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ABSTRACT 
Two possible variables of the McKenzie/Stoughton blanching assay, namely 
amount applied to the test site and occlusion time have been investigated. 
Subsequently, two topical steroid preparations, Synalar cream (0,025% 
fluocinolone acetonide) and Betnovate cream (0,1% betamethasone 17-
valer ate) were extemporaneously diluted with five and six placebo bases 
respectively. 
Taking cognizance of the two possible variables, these diluted preparations 
were assessed in vivo using a modified version of the McKenzie/Stoughton 
blanching assay for blanching activity over a 14 month period. It was 
found that the base E45, which is slightly alkali, had the greatest 
effect on both preparations. In the case of betamethasone 17-valerate 
this base c aused the conversion to the less active isomer, betamethasone 
21-valerate whereas at the end of the 14 month test period it was found 
that the Synalar/E45 dilution contained no fluocinolone acetonide. 
Quantitative analysis of all the diluted preparations by high performance 
liquid chromatography using a reverse-phase system was performed. 
The data obtained f r om the systematic stUdies of the effects of varying 
concentrations and occlusion times wer e pr esented at the Eleventh 
National Congress of the South African Pharmacologi cal Society. 
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STRUCTURES OF CORTICOSTEROIDS STUDIED IN THIS WORK. 
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1 • INTRODUCTION 
Topical steroids account for about half of the prescriptions given to 
patients in the practice of dermatology .1 There were 9 , 500 , 000 
prescriptions written for topical corticosteroids in the United States2 
in 1969 and in Britain in the same year 4% of the National Health Services 
prescription expenditure was for topical corticosteroids. 3 The main 
reasons for this ar e that topical corticosteroids are effective and 
relatively safe. 1 
This widespread use has created a need for a reliable method of in vivo 
testing of these drugs. Clinical trials are laborious and difficult to 
mount as well as being unsuitable for the screening of large numbers of 
drugs. Patients suffering from dermatological complaints are likewise 
not ideal subjects for the testing of topical ster oid preparations as it 
is difficult to obtain standardised l esions which are necessary for 
comparison of results between patients. 4 Thus various methods have 
been devel oped for the screening of topical steroids in animals and 
human volunteers. 
1 .1 BIOASSAYS US ED TO ASS ESS TOPICAL ST mOID ACTIVITY 
Various workers have attempted to substitute inflammation caused by 
natural disease with experimentally induced inf l ammation in healthy 
volunteers . 
A large number of chemically injurious substances have been used to 
artificially produce inflammation. In 1956 Scott and Kalz 5 investigated 
results obtained with nitric acid and mustard oi l and in 1959 Witkowski 
and Kligman6 used croton oil to induce inflammation . Croton oil 100%7 
or a mixture containing pyridine 20% , water 5%, diethyl ether 74% and 
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croton oil 1%8 has been used in various modifications of a technique 
described by Tonelli et al. in 19659 which is commonly known as the rat 
ear assay. 10 " 11 Ortega et a le and Burd1ck adapted this method for use on 
human skin. Kerosene was used as the inflammatory inducing agent in 
experiments carried out by Zaynoun and Kurban12 and Kaidbey and Kligman13 • 
The latter established a corticosteroid rank order which correlated well 
with clinical efficacy. Tetrahydrofurfuryl alcohol was used as the 
irritant by Schlagel and Northam in 195914 and by Brunner and Finkelstein 
in 196015, 
Topical steroid activity has also been evaluated by assessing their ability 
to suppress erythema produced by pyrexal16 and ~ dermatitis17 
experimentally induced in humans by patch application of Rhus oleoresins. 
The abili ty of corticosteroids to reduce the size of weals induced by 
histamine on human skin when the histamine was introduced by the pinprick 
18 
method has also been used as an assay method . . The activity of 
fluocino lone acetonide has been determined by studying its ability to 
" 11" d d 19 suppr ess exper1menta y 1n uce eczema. 
All these methods suffer from the same drawbacks in that they are painful 
and unpleasant for the volunteer and that it is di fficult to reproduce a 
standardised inflammation. 4 
Ultra violet light can be used in the same way as chemical irritants to 
produce inflammation. Epidermal cell deaths, increased mitosis, hyper-
plasia, cellular exudation and vasodilation ar e all a result of injury to 
" "1" h 20 the sk1n by ultra v10let 19 t. Application of topical steroids after 
exposure to ultra violet light resulted in decreased erythema , but Burdick 
et al. 21 found that it was not only the time of application that was 
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critical but also the amount of exposure to ultra vio l et light. It was 
found that it was necessary to determine each individual's "minimum 
erythema dose" in order to obtain good discrimination between test 
compounds. 
22 .. . In 1940 Wolf observed that 1f adhes1ve tape was appl1ed to the skin 
surface and sharply pulled off, local tissue damage could be produced. 
23 In 1957 Wel ls suggested that this particular damage and repair stimulus 
might be suitable as a steroid assay method. It was found that hydrocortisone 
applied after stripping caused a decrease in vasodilation, the maximum 
response occurring after 12 hours. H .. 24- 26 f I owever some 1nvest1gators e t 
tha t the skin stripping method had the disadvantage of removing the 
physiological barrier to absorption. 26 In fact it was demonstrated that 
damaging the skin by removing its superficial barrier will allow up to 75% 
of a corticosteroid to pass through it. Such variability in percutaneous 
absorption will depend on the extent of cutaneous damage. 27 This method 
a lso suffers from the disadvantage in that it is both painful and unpleasant 
4 for the volunteers. Nevertheless the method has been employed in the 
f f d · I . . 28-33 development 0 ormulate top1ca cort1costero1ds. 
34 The Rat Thymol ytic Anti-Inflammatory Activi ty assay and the Anti-Granuloma 
35 
assay are systemic assays for corticosteroids but can be used as a 
preliminary indication of possible topical corticoid activity.8 
In 1971 Fisher and MaibaCh36 suggested that the well documented antimitotic 
effect of corticosteroids might be used to assay new corticoids, as the 
antimitotic activity seemed to be related to the steroid activity. In 
37 1973 Marks et al. u sed a method of artifically boosting the mitotic rate 
of the dorsal skin of the hairless mouse . by stripping the skin five or six 
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times with adhesive tape. Topical steroids were subsequently applied to 
the "stripped" skin and the area occluded. By this method they were able 
to show that it was indeed possibl e to use the antimitotic effect as an 
assay for topical steroids. 
38 Jarrett and Spearman correlated thinning of the epidermis wi th a reduction 
in mitotic activity and subsequently compared five commercially available 
creams by comparing their thinning action on the mouse tail epidermis.39 
Certain ointment bases when applied to guinea pig skin produce a measurable 
and reproducible epidermal thickening. 40 41 Barnes et al. were able to 
relate the suppression of these changes to the type and concentration of 
corticosteroid used and the nature of the base . This method is therefore 
useful in determining the most suitabl e base as well as the efficacy of 
the steroid. 
The effects of anti-inflammatory corticosteroids on fibroblasts, which 
form the matrix and fibrous substance of the dermis, were demonstrated 
in vivo by Dougherty and SChneebeli.42 Fibroblasts reac t to corti co-
steroids with morphological changes which can be direct l y correl ated with 
corticosteroid anti-inflammatory activity.43 This inhibition of f ibroblast 
growth can be used as an in vitro assay for corticosteroid activi ty'. 44 
45 Scholtz and Dumas in 1972 developed a method of corticosteroid testing, 
using patients wi th chronic stabilised psoriasis. Chronic stabilised 
patients were used because in any given plaque of psoriasis there is a 
consistency in the degree of activity and severity f rom one part of the 
1 . h 46 eSlon to anot er e Good correlation was achieved between results 
obtained from the psoy·iasi s assay and animal assays "Then deter mining the 
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" "d 46 potency of fluoclnolone acetonl e . 
The main advantages of the psoriasis bioassay are that the inhibitory 
effect upon the epithelial prol iferation is t ested . The test is 
carried out on a human dermatosis which is one of the most important 
indications for the use of corticosteroids, and t he patient suffers no 
additional trauma. The disadvantages of the test are that the appropriate 
patients must be avai labl e , the test is only semi-quantitative , certain 
corticost eroids whrch have no antiproliferative action are not suitabl e 
for the test ,47 and the patients must be selected by trained personnel. 
1. 2 THE HUMAN VASOCONSTRICTOR ASSAY AS A MEl'iSURE OF TOPICAL STEROID 
ACTIVITY 
In 1950 Hollander et al . reported that intra- arti cular steroids produced 
blanchi ng of the engorged synovial membrane in rheumatoid arthriti s48 and 
in 1952 Aston and Cook observed vasoconstric ti on in superficial corneal 
vascularization treated with subconjunctival steroids.49 
It was not until 1962 however , that McKenzie and Stoughton , 50 after 
observing that topical steroids under occ lusion ,51 produced pallor of 
psori asis l esions and of the surrounding normal skin , realized that this 
b l anching might be used as an index for percutaneous absorption of steroids. 
1. 2 .1 Alcoholic Vasoconstrictor Studies 
The McKenzie/Stoughton assay t echnique involved the appl i cation of solutions 
or suspensions of steroids in 95% ethanol to normal healthy skin both in the 
occluded and unoccluded mode. By this method they were able to determine , 
using the degree of skin pallor as the index, that occlusion produced an 
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increase in penetration by a factor of approximately one hundred. 
. 52 . . ff d . McKenzIe, uSIng the vasoconstrIctor e ect, teste a number of topIcal 
steroids and was able to indicate that acetates were better absorbed than 
their parent alcohols , which were in turn better absorbed than phosphates. 
With regard to triamcinolone he found that the acetonide greatly increased 
penetra tion. He also found that precise assessment of the potency of the 
steroid was impracticable using intradermal injections . since vasoconstriction 
lasting several hours may be seen around an intradermal injection of any 
sort. 
In a similar assay to that used by McKenzie , McKenzie and Atkinson53 assayed 
betamethasone and 23 of its ester s . They concluded that despite its low 
precision the vasoconstrictor assay is of value for the screening of 
potentially active topical steroids. 
In 1966 after a modification of the technique by Sarkany et al.,54 
MCKenzie55 pointed out that he felt it was impossible to grade accurately 
the degree of pallor and that the importance of the test was in the use 
of high di l utions. zaun56 in 1966 also concluded that the vasoconstrictor 
test was not sufficiently sensitive for the determination of quantitative 
differences between compounds. 
57 fl · h· Baker and Sattar were unsuccess u In t elr attempts to grade the pallor 
that they observed in an assessment of four fluocortolone analogues, but 
by using the presence or absence of pallor they were able to differentiate 
between thr ee fold increments in concentration of the steroids. This 
experiment also took into account that the steroi ds were deposited on the 
skin surf ace by eliminating all air movement that could cause some of the 
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steroid to be lost. 
In 1968 Chl'ld et al. 34 examl'ned Sl'X . 11 'I bl t ' 1 t 'd _ _ commerCla y aval a e oplca s erOl s 
for vasoconstrictor activity in man, systemic anti-inflammatory activity in 
rats and mice and progestinal activity in rabbits. Good agreement was 
obtained between ranking order of topical activity and ranking order of 
systemic activity. 
58 Stoughton tested five glucocorticosteroids suspended or dissolved in 
95% ethanol for vasoconstrictor potency in vivo and the abili ty to penetrate 
skin in vitro. Unfortunatel y owing to a lack of randomization , which is 
essential , 51 these results are dubious. 
Place et a159 modified the vasoconstrictor assay and investigated serial 
dilutions of several corticosteroids. The assay was modified by duplicating 
applications, randomised differently on both arms of the same volunteer. 
Test sites on the volunteers arms were outlined with silicone grease. In 
this assay particular attention was paid to experimental variables. 
The method used by Place et al. 59 was modified by Moore-Robinson and 
Ch ' ,60 d R b ' 61 rlstle an Moore- 0 Insan. The modification of the Place et al. 
assay were :-
(1) Occlusion time was reduced . 
(2) After remova l of the dressing the arms were washed with soap and water. 
(3) A scale of from 0 to 3 was used to quantitate the degree of vaso-
constriction. 
(4) Blanching was "read" at two time intervals, 8 hours and 24 hours 
after application. 
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By this method six corticosteroids dissol ved in ethanol were investigated 
and statistical differences demonstrated. 
The method of Moore-Robinson and Christie was extended by Granier 62 who 
observed blanching at three different time intervals, namely 8, 12 and 
24 hours after application. 
In 1972 Burdick63 modified the Moore-Robinson and Christie assay technique 
by increasing occlusion time to 18 hours and in 1973 Weirich and Lutz64 
again modified the assay by using a 0 to 2 scale and observing the 
responses at 2, 4, 8, 24 and 32 hours after an occlusion time of 16 hours. 
Falconi and Rossi 65 considered that the McKenzie/Stoughton method of 
evaluating vasoconstrictor activity was time consuming and contained a 
possible source of error in that the alcoholic solutions had a tendency 
to spread uncontrollably over the skin surface. They modified the 
technique by incorporating the test compounds into coded, glassine backed 
1 cm squares of thin absorbent paper which were applied to the skin surface. 
However before application of the squares each arm was shaved if necessary , 
oils removed with a mixture of alcohol and ethyl ether, and a "small" 
amount of 5% tincture of thurfyl nicotinate applied to the test site. 
This pre-treatment does not appear to be standardised and could possibly 
introduce a source of error. The degree of blanching was evaluated on 
a 0 to 3 scale. 
66 In 1974 Engel et al. used an unmodified form of the McKenzie/Atkinson 
test, but used two parameters to quantify the response, namely spot diameter 
and blanching. Both responses were graded on a -, +-, + and ++ scale. 
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It was shown that this method was sufficiently quantitative to be used 
in structure activity relationship investigations. 
Barry and Brace in 1975 67 assessed the topical activity of eight novel 
anti-inflammatory steroids using a modified form of the vasoconstrictor 
assay. After evaporation of the ethanol the sites were occluded for 6 
hours and thereafter assessment of the blanching was made using a 0 to 4 
scale wi th half point ratings. Seventeen reading times a llowed the 
determination of complete blanching profiles for each steroid. Three 
methods of statistical analysis were used to rank the steroids ; summed 
% total possible score , area under the blanching profile and square root 
transformations of sum scores divided by the nurr,];.Er of volunteers. 
1.2.2 Studies of Vasoconstriction in Other Solvents 
The use of solvents which increase the transport of medicaments t hrough 
the skin, such as dimethylsulphoxide (DMSO), dimethylformide, 
dimethylacetamide and tetrahydrofurfuryl alcohol has been widely studied. 68 
Stoughton and Fritsh69 found that DMSO enhanced the penetration of alcoholic 
solutions of fluocinolone ac etonide and Stoughton70 found that within a 
few minutes after application to the surface of human skin, hydrocortisone 
and fluocino lone acetonide in the presence of DMSO are established in a 
protected reservoir in the stratum corneum . (See section 1.4) 
In 1966 Tissot and Osmunsden71 using a modification of the McKenzie/ 
Stoughton vasoconstrictor technique screened a number of different 
organic solvents for their potential to serve as effective vehicles for 
the administration of f luorometholone. It was found that the potency 
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of fluorometholone in the vasoconstriction test was affected by these 
solvents and that small chemical differences in the configuration of the 
solvent molecules influenced efficacy. 
Triamcinolone acetonide and triamcinolone cumarilate in four solvents 
were studied by Altmeyer and Zaun in 1974 using a reflex photometric 
. 72 technlque. 
Several groups of substances have been shown to have penetrant properties; 
for example , the protein denaturing substances , salicylic acid , l.atic acid 
and urea. These penetrants have been studied in vitro. 73- 74 
1.2. 3 Studies of Vasoconstriction in Formulated Products 
Solvent studi es are useful in the development and establ ishment of rank 
order for topical steroids. These studies do not however take into 
account the influence of the pharmaceutical formulation on the avai l abili ty 
of the steroid . It has therefore become necessary to establish bio-
availability for the formulated product. 
Barrett et al . 75 in 1964 observed the vasoconstrictor activity of 
betamethasone 17-valerate incorporated into four bases : Aqueous Cream 
B . P., Oily Cream B. P. , white soft paraffin and macrogo l ointment . No 
significant differenc es in the degree of b lanching were observed , although 
a larger area of vasoconstriction was obtained for the macrogol ointment 
formul ation. 76 Sarkany et al. extended this work using the four vehicles 
but incorporating betamethasone 17-valerate , fluocinolone ace tonide , 
hydrocortisone acetate and hydrocortisone alcohol. Similar results to 
those of Barrett et al. 75 were obtained for the betamethasone 17-valerate 
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but the fluocinolone ac etonide failed to produce any consistent response 
wi th the different bases . Hydrocortisone acetate and hydrocortisone 
alcohol, when incorporated into the above bases failed to produce any 
activity , but when formulated into dimethylacetamide and tetrahydro-
f urf uryl alcohol bases blanching was obtained. 
In a subsequent s tudy , Bar rett et al . 77 noted tha t micronization of the 
fluocinolone ac etonide improved t he activity which was further improved 
by the addition of 5% propyl ene glycol to t he base . 
Caldwell et al . 78 dissolved 0 , 5% beclomethasone dipropi onate in propylene 
glycol and incorporated 5% of this solution into white soft paraffin . 
The resulting ointment was more active in the vasoconstrictor test than 
an ointment containing the same concentration of active ingredient i n a 
microcrystalline suspension. 
To compare the rel ative vasoconstrictor potentia l s of three stero ids , 
fluoc inolone acetonide , triamcinolone ac etonide and hydrocortisone a lcohol ) 
Reid and Brooke79 sel ected a common base that , from preliminary work, had 
been shown to permit the maximum percutaneous absorption of the three 
s t eroids . A dimethyl acetamide/macrogol formulation was choosen as the 
"universal base". The activities of the three steroids were compared 
using a 1 to 4 grading based on the area and degree of pallor. Li ttle 
difference was noted between the vasoconstric tor potentials of fluocinolone 
acetoni de and triamcinolone ac etonide but both of these were a bout t wice 
as effective as hydrocortisone alcohol. 
In 1969 Busse et al . 80 studied the release of bet amethasone 17-valerate 
and 21-desoxybetamethasone 17-valerate from various ointment bases. As 
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" " "75-76 h" h 1 " " " In preVIOUS studles, 19 re atlve potencIes were obtaIned when 
propylene glycol was incorporated into the ointment. 
Christie and Moore-Robinson in 197081 assessed the effects of various 
bases on the vasoconstrictor response. A propylene glycol ointment 
base was considerably superior to the base that did not contain this 
ingredient . 82 Ostrenga et al. were also able to demonstrate that ointment 
delivery syst ems were greatly improved when the steroid, in this case 
fluocinonide, was completely dissolved. The effects of three different 
bases on the absorption of fluocinolone acetonide were studied by Granier. 62 
A non-emulsified , anhydrous fatty alcohol/propylene glycol cream base , 
FAPG , was shown to have better absorption Characteristics than the more 
conventional creams. The effect of ointment base composition on the 
f h 7 b "" d b 1 1 83 release 0 betamet asone 1 - enzoate was lnvestlgate y Pep er et ~. , 
Soft Paraffin/propylene Glycol and Soft Paraffin/Isopropyl Myristate gave 
significantly higher results than conventional bases. 
Coldman et al. 84 evaluated several commercially available topical steroid 
preparations in the unoccluded mode wi th a short duration of appl ication. 
Two ointments , both containing the same steroid in the same concentration 
but compounded by different manufacturers were included in this assess-
mente One ointment was superior and on examination it was found that 
the steroid was in solution or fine particles whereas,in the less active 
preparation the steroid was in a c rystalli ne state. Thus correct 
formulation of the topical vehicle is important in order to allow the 
steroid to exert the maximum effect. It was also noted in this test 
that a placebo preparation had a vasoconstrictor activity which could 
account for as much as 50% of the response as in the case of White Soft 
Paraffin B.P. 
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85 Subsequently Coldman et al. compared fluoc inonide in FAPG base with, 
and found it to be superior to, commercially available preparations of 
betamethasone 17-valerate, triamcinolone acetonide and hydrocortisone. 
In 1972 Brudick ,11 using a short application time of 6 hours investigated 
the effects of two different steroids in two different bases and was able 
to emphasise the importance of the correct base. The shortening of the 
appl ication time was shown to a llow better discrimination between the 
release characteristics of the bases. As an extension of the work done 
82 . 21 by Ostrenga et a l. , Burd1ck et al. compared several commercially 
available preparations with a fluocinolone acetonide ointment in which 
the steroid had been dissolved in a mixture of propylene glycol and 
propylene carbonate. The short application time was again used. It 
was concluded from this trial that the most logical basis for comparison 
is to calculate the area under the curve for each formulation. (See 
section 2.4) 
86 In 1974 Poulsen et al. compared three different methods of visually 
assessing blanching . The three techniques were , the presence or absence 
of pallor , grading the degree of pallor on a 0 to 3 s cale and a technique 
involving paired comparisons at adjacent si tes . This latter technique 
was f ound to improve the assessment. 
87 In 1972 Stoughton ,using the unoccluded mode , compared a number of 
commercially available preparations. 84 However, unlike Coldman et al., 
a long (20 hours) appl ication time was used. Ointment vehicles were 
generally found to be superior to creams and l otions. This could be 
due to the occlusive nature of the ointment vehicle or as a result of 
the high placebo effect of white soft par affin . 84 
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88 Barry and Woodford evaluated thirty proprietary creams and gels using 
excellent modifications to the vasoconstrictor test . The test si tes 
were occluded for 6 hours which allowed better dis·crimination between 
the products. Grading was done on a 0 to 4 scale with hal f point ratings. 
Eleven readings were taken from 6 to 96 hours after application which 
allowed the determination of complete blanching profiles. The retention 
of the steroid was a l so assessed in selected volunteers by re- occluding 
the sites for 12 hours , 8 , 12 and 14 days after application . (See 
section 1.4) 
All readings were taken by the investigators except the 9 and 12 hour 
readings . These were "read by the volunteers It who "were instructed 
to use similar conditions " . 89 This change in observers is not entirely 
satisfactory , especial l y as the readings taken by the v olunteers are 
approximately at the time when the maximum intensity of blanching has 
been reached . Howev er , as this is a comparative technique any small 
differences will be rel ative and should not alter the results significantly. 
Woodford and Barry90 observed the bioavailabili ty and activity of 
betamethasone 17-benzoate in a gel and cream and compared these formulations 
wi th several proprietary fo.rmulations. In this test it was found that the 
betamethasone 17-benzoate was significantly less active than a betamethasone 
17- valerate preparation. However in a previous study it had been shown 
that these two steroids were equival ent when dissolved in alcohol. It 
could be possible that the betamethasone 17- benzoate preparation had 
not been optimall y formul ated. 
Extending their work on creams and gels Barry and Woodford91 compared 
the bioavailabilities of thirty one ointments , and subsequently compared 
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92 
six proprietary hydrocortisone creams. Barry and Woodford have there-
fore evaluated, for vasoconstriction, and hence bioavailability, a large 
proportion of topical steroid products on the United Kingdom market . 
In 1977 these two investigators again evaluated nine formulations for 
blanching activity.93 Two of these formulations were of an experimental 
nature whereas the others were proprietary formulations. "Two of the 
proprietary formulations were marketed in the U. S . A. but not in the U. K. ". 
The investigators made no mention of the manner in which the '~.S.A. 
formulations" were imported. It is felt that the method of importation 
is important as it may be possible that the physicochemical nature of the 
base may change when subjected to extreme conditions which could have 
resulted during importation. 
94 Barry and Woodfo r d used a non- occluded multiple dose regimen in an 
att"empt to mimic a therapeutic regimen. It was found that the blanching 
response first increased but then diminished with continued application 
f " d " d 95 over a lye ay perlO • A "resting period" of two days was a l lowed 
before subsequent administration. After the resting period , a 
response was again apparent , but this also diminished with continual 
application. The maximum response and the area under the blanching 
curve for the second week was less than those of the first week. This 
work may have significant importance in patients who become resistant 
to topical corticosteroid preparations , in that the vasoconstrictor 
test could be used to determine the optimal dosage regimen. 
The blanching assay has been used specifically to optimise the propylene 
glycol concentration in formulation development. 96 In 1976 , Bl uefarb et al. 
used the test to optimise the propylene glycol concentration for a bas e 
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containing 0,05% diflorasone diacetate . In this test a 0 to 3 scale 
with half point ratings was used and the sites were left unoccluded for 
6 hours or occluded for 19 hours . The 6 hour unoccluded study 
derr.onstrated that the formulation containing 15% propylene glycol was 
significantly better than other formulations, however a 6 hour occluded 
test did not show any marked differences between formulations. Significant 
differences were shown under 19 hours occlusion where the 15% formulation 
again outperformed all but one of t he other formulations . 
1.3 THE MECHANISM OF BLANCHING 
The exact mechanism of b l anching produced by topical steroids is not 
c l ear. Several investigators have implied that a rel a t ionship exists 
between noradrenalin (NA) and corticosteroids, but others have demonstrated 
that NA is not the only factor invol ved . Fritz and Levine97 have shown 
that vasoconstriction by NA in the mesoappendix of adrenalectomised rats 
does not occur unless the cortical extract is appl ied topical l y. It 
was thus suggested that corticosteroids may support vascular tone by 
potentiating the pressor action of NA . Using the rabbit ear49 and 
the mesoappendix of the adrenalectomi s ed rat98 it has been suggested 
that steroids increase the sensitivity of blood vessels to NA. Reis99 
demonstrated that adrenocortical steroids have a local and direct effect 
on normal human bulbar conjunctival vessels as well as potentia t ing NA. 
. 1 00 h f d . d f h .. . h JuhlIn " ow-ever, oun no eVl ence 0 sue a potentlatl.On In t e 
vascular react ion of normal skin treated with fluocinolone acetonide. 
It was therefore assumed tha t blanching was due to a vasoconstrictor 
effect of the steroid per se. 
Frank et al . 101 and later Altura102 showed that steroids did not act 
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directly by constricting any of the muscular components of the capillary 
bed but enhanced vascular reactivity to various constrictor s while 
suppressinghistamin~ bradykinin and alcohol induced vasodilation as 
well as potentiating NA. 103 Solomon et al. suggested that corticoster oids 
may be capable of releasing NA from cutaneous stores which had been shown 
to be present by Moller,104 but the precise location is unknown. 105 ,106 
103 Solomon et al. studied the effect of the NA blocking agent guanethidine 
on vasoconstriction and were able to demonstrate that guanet hidine did 
inhibit vasodilation in normotensive subjects and thus suggested that 
steroid vasoconstriction was mediated by NA released from these cutaneous 
stores. 
Wolf et al. 107 were able to demonstrate that topically applied cortico-
steroids potentiated catecholamine induced vasoconstriction . This effect 
was blocked by phentol amine, but not by propranolol and hence it was 
suggested that this action is mediated through the increased sensitivity 
of alpha adrenergic receptors. 
Du Vivier and Stoughton95 demonstrated that it was possible to induc e 
tachyphYlaxis to topically applied steroids. As a result of this they 
suggested that the NA "stores" might be situated in nerve vesic l es and 
that topically applied steroids might act indirectly by releasing this 
endogenous NA , or influencing its metabolism or re- uptake. Alternativel y 
it was suggested that the steroid may attach itself to a rec eptor site, 
which might be specific for each different steroid or a general r eceptor 
f or al l steroids, causing the re l ease of the intracellular mediator 
adenosine monophosphate or more likely guanosine monophospate. 
Guanosine monophosphate is a vasoconstrictor and can be stimulated by alpha 
.. 108 
receptor actlvlty. 
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1 .4 THE SKIN AS A CORTICOSTEROID RESERVOIR 
The existence in the skin of a depot or. reservoir for topical cortico-
109 
steroids was suggested by Malkinson and Fer guson. . k 110 V1C ers 
demonstrated the existence of this reservoir and found it to be situated 
in the stratum corneum and of considerable capacity. The technique used 
by Vickers to demonstrate this depot was the same as that used by McKenzie 
50 
and Stoughton. A stream of warm air was used to promote rapid drying 
of the test sites. This did not take into account that the steroid is 
deposited on the skin surface and could have lead to variation by lass 
of the steroid . The test areas were occluded for 16 hours . On 
removal of the occl usion blanching was visible but faded after 10 to 16 
hours . The test sites were subsequent l y re- occluded every " two to 
three days " and on removal of the occlusion blanc hing was again visible. 
In some volunteers it was possible to demonstrate blanching up to 15 
days after the initial application. The existence of this resevoir has 
been confirmed by a number of workers. 70 ,90 ,11 1 
22 Through a series of stripping experiments as described by Wolf and by 
the use of intradermal injections, Vickers was able to locate the reservoir 
in the stratum corneum. However Feldman and Maibach 127 suggested that the 
deeper layers were also i mplicated. Subcutaneous fat has also been 
h . . f d 27 suggested as t e posslble slte or the epot . 
The retention of a corticosteroid in the skin should also be considered 
f ff " I ' 27 h ' f as a actor a ectlng 1 ts re atlve potency as t e eXlstence 0 a 
reservoir allows the steroid t o be released slowly over a long period 
of time . Barry and Woodford88 , 90,91 determined that the degree of 
blanching following re-occlusion of proprietary formulations was 
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proportional to the ranking order of the preparations. However this 
was only in the case of the more potent steroids as they were unable to 
demonstrate the existence of a depot for hydrocortisone formulations. 92 
Barry and Woodford94 in their assessment of vasoconstriction using a 
multiple dosage regimen, found that the reservoir for the more potent 
steroids was erratic and it was again not possible to demonstrate a 
reservoir produced by hydrocortisone preparations. 
1.5 THE CORRELATION OF VASOCONSTRICTION WITH CLINICAL EFFICACY 
The MCKenzie/Stoughton blanching test is based on the property of cortico-
steroids to produce measurable pallor of the human skin. However 
37 
according to Marks et al. the disadvantage of this test lies in the 
fact that although the vasoconstriction is a component part of the 
therapeutic effect it does not pl ay the leading role. It has therefore 
become necessary to compare the vasoconstrictor activity of a topical 
corticosteroid with the clinical efficacy of that steroid. 
The strong degree of parallelism between blanching activity and clinical 
f f 11,46,47 , 77 , 78 , 88 efficacy has been the subject 0 a number 0 papers. 
Reid and Brookes79 correlated the blanching activity of three corti co-
steroid ointments, hydrocortisone (1%), fluocinolone acetonide (0 ,025%) 
and triamcinolone acetonide (0,025%) with their clinical efficacy in a 
group of patients with eczema. The results of both assessments were 
the same , with fluocinolone acetonide being s lightly superior to triamcinolone 
acetonide which in turn was better than hydrocortisone. 
. 46 f d d l' b h bl h' .. f Moore- Roblnson oun goo corre atl0n etween t e anc lng actlvlty 0 
fluocinolone acetonide and its clinical efficacy. 
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Whitfield and MCKenzie112 using the blanching assay compared a hydro-
cortisone 0 , 1% two phase cream with a 1% hydrocortisone B. P.C . cream. 
The two phase formulation produced blanching in 9 out of 10 volunteers , 
whilst the B. P.C . formulation produced a response i~ only 1 volunteer . 
The clinical efficacy of both these creams correlated well with these 
resul ts. 
The blanching assay is reliabl e and quick whereas other screening tests 
h b b ··· h 1" ff . 11 3 ave een shown to e lnconslstent Wlt c lnlcal e lcacy . Thus the 
human vasoconstrictor test is an excellent method for screening new cortico-
steroid derivatives for activity , and for comparing existing formulations. 
It also has the advantages that heal t hy skin is used, it is not painful 
to the volunteers and a number of preparations can be evaluated 
simul taneously . 
1 . 6 'IRE EFFECT OF EXTEMPORANEDUS DILUTION OF TOPICAL CORTICOSTEROID 
FORMULATIONS 
There is a wide range of topical steroid preparations on the market which 
can broadly be divided into three categories ; highl y ac tive , moderately 
active and mildly active. If a pr actitioner wishes to avoid a potent 
. d h . 1 h Id b . b 'ld . 11 4 sterol , t e ratlona approac wou e to prescrl e a ml er preparatlon . 
However despite this , practitioners continue to prescribe extemporaneously 
diluted topical steroid preparations. Keipert115 felt that most 
commercial preparations were unnecessarily strong and by dilution the 
preparation would be cheaper and lessen the risk of significant absorption. 
A nurr,ber of surmises have appeared in the literat ure concerning 
extemporaneous dilution of topica l steroids. 116 , 117 These have 
- 21 -
generally arisen as a result of theoretical considerations with very 
little,if any,experimental back up. These theoretical considerations 
c an be divided into three main categories; pharmaceutical, bacteriological 
and biopharmaceutical. 
1.6.1 Pharmaceutical Considerations 
Manufacturers take a great amount of trouble to produce sophisticated 
vehicles in which to incorporate topical corticosteroids. The components 
of these vehicles have been shown to be compatible with each other and the 
efficiency of the vehicle as a corticosteroid donor has been demonstrated. 
It is therefore reasonable to suggest that extemporaneous dilution of 
t hese vehicles would have a deleterious effect , and as such manufacturers 
do not recommend dilution of their topical corticosteroid formulations. 
The highly sophisticated vehicle , FAPG base, will crack if diluted with 
. 117 
many creams or olntments. 
It would also be possible to inadvertently choose a diluting medium of 
opposite ionic type to the proprietary product resulting in a breakdown 
f h 1 · 118 o t e emu S10n. The British Pharmaceutical Codexl1 9 and Marti ndale 
Extra Pharmacopoeia120 recommend certain bases with which to dilute 
proprietary topical corticosteroid preparations shoul d a dilution be 
necessary . It is also stated in the monographl19 that these 
extemporaneous preparat ions must be used within one month of manufacture 
and that Betamethasone Cream diluted with a base of a l kaline pH will 
accelerate the conversion of the betamethasone 17-vale- ate to the less 
active betamethasone 21-valerate. However, nothing has appeared in 
the literature in support of these statements . 
- 22 -
116 In an article containing no experimental evidence , Mooney and Pearce 
found that in an alkaline vehicle, such as E45 cream, t he fluocinolone 
acetonide in Synalar and the fluocinonide in Metosyn underwent oxidative 
degradation at the 11 and 21 positions . "Thus a dilution of 20% Metosyn 
in E45 cream loses 50% of its steroid concentration after one month's 
storage at 230 C." 
Topical steroids in ointment vehicles are generally diluted with white 
f ff ' 121 so t para In. h ' h h b ' f 122 , h T 1S was t oug t to e sat1s actory but now W1t 
the more sophisticated ointment bases , that is, ointments containing a 
fine dispersion of steroid dissolved in propylene glycol, i t has been 
suggested that it would be difficult to maintain this dispersion on 
d ' l' d h ' , 'h h , 11 7 ,1 23 extemporaneous 1 ut10n an t at tr1turat1on m1g t cause p ase separat1on. 
1. 6 . 2 Bacteriological Considerations 
During dilution of topical corticosteroid preparations pathogenic bacteria 
may be introduced into the vehicle. Strains of Pseudomonas have been 
'f 1 ' 1 d ' , 124 1sol ated rom extemporaneous y d1 ute top,cal stero1d c r eams. 
However , these surveys of bacteriological content of diluted topical 
steroid have general ly been carried out in hospital s where there is 
u sually a higher bacterial count . 
Proprietary topical corticosteroid prepar ations are manufactured under 
i deal , carefully controlled conditions and preservatives are added to 
, 116 122 those preparations in which microorganisms can be susta1ned.' It 
is possible that on dilution , the preservatives may be inac tivated due 
to incompatibility or excessive dilution , 118 but there is no experimental 
evidence to support this and an investigation is required to determine 
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the actual extent of bacteriological contamination and what effect 
dilution has on the preservative. 
1.6.3 Biopharmaceutical Considerations 
The release of topical corticosteroids is dependent on the nature of the 
vehicle in which it is incorporated. In the development of a new topical 
steroid formulation , manufactures go to a great deal of troubl e to ensure 
the optimum release from the vehicle,as incorrect formula t ion will inhibit 
th e release,. and consequently, the activi ty of the corticosteroid. Dilution 
of proprietary fo.rmulations, may produce a preparation which appears to be 
physically acceptable , but which has poor rel ease characteristics. 125 
Topical corticosteroi d vehicles general l y contain a critical amount of 
propylene glycol in which the corticosteroid is dissolved. 96 Over-
solubilization of the steroid with propylene glycol will result in the 
steroid preferentially remai ning in the vehi c le., whereas under-solubilization 
wi ll cause the steroid to revert to the crystalline form , which is less , 
active. It is possible that on diluti on the corticost eroid becomes 
ei ther over. 'or under-..solubilized •. which would result in a poor release 
and consequently a poor activity. Alternatively it is possible that 
t he corticosteroid could be precipitated if the diluting base contained an 
large proportion of water in which the steroid is not readily soluble. 117 
It is a l so possible that on dilution the resultant base could be superior 
t o the original base either due to a better release abili ty or t o the 
occlusive nature of the base being increased. The latter would be expec t ed 
if a cream formulation were diluted with an ointment base. 
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woodford89 noted that extemporaneous dilutions of Betnovate cream stored 
for short periods of time before being examined by the blanching assay 
were li ttle affected by the di l uent and suggested a more thorough investigation. 
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2. METHODS 
2. 1 THE BLANCHING ASSAY 
Proprietary formulations and placebo bases were purchased from a local 
pharmacy or manufactured according to B. P. C. procedures. No manufacturev's 
samples were used. 
2.1. 1 Volunteers 
Healthy male and female Caucasians were screened to determine their response 
to a standard preparation , Betnovate cream (betamethasone 17-valerate 0 ,1 %), 
applied to the flexor aspects of either forearm and occluded for 6 hours. 
Only those volunteers who demonstrated a positive response to the standard 
and who had not received either topical or systemic corticosteroi ds for at 
least four weeks were included in the investigations. 94 ,95 Where possible , 
the same volunteers were used when preparations were to be investigated 
routinely. 
2. 1. 2 Mode of Application 
Adhesive labels ( "Self Seal" Ref. 2438, Gateway Fine Stationery) from 
which two independent 7 mm squares had been punched were used to mark 
the flexor aspects of both forearms producing 12 application sites. 
One set of appl ications was occluded, the other left unoccluded. The 
occluded experiments were performed using a nonporous plastic film, 
12 (Blenderm Surgical Tape No. 1525 25 mm x 4 , 5 mm). Six separate strips 
89 
of sufficient length to prevent separation of the tape from the arm was 
f d 1 · 81 ound to re uce tunne llng. In the unoccluded experiments the sites 
were protected with a cardboard frame to prevent accidental removal of 
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the test preparations. In both modes of application the adhesive labels 
were l eft in place for the duration of the application and the arms were 
not bandaged. 
The pr eparations were coded by a person not involved directly with the 
investigation as were the application charts. Four 7 mm stripes of 
each preparation, approximating to 3 , 03 mg (see section 3. 1) were appl ied 
to each discrete application site. The standard mass was extruded from 
1 ml disposable tuberculin syringes , the needles of which had been cut 
to 5 mm in order to facilitate the extrusion of the formul ated product. 
The syringes were filled immediately prior to use to prevent and minimise 
any possible int eraction between the preparation and the plastic syringe. 
The syringes were di scarded after use. 
The extruded formulations were spread on the 7 mm square application sites 
using a different glass rod for each preparation. 
The formulations were allowed to remain in contact with the applica t ion 
si tes for exactly 6 hours after which time the occlusions and protections 
were removed. The adhesive labels and plastic occlusions were removed 
1 1 d h d . bl .. 23 f s ow Y so as to re uce eryt ema an to prevent POSSl e str'PP,ng 0 
the epidermis . The sites were washed by the volunteer using soap and 
warm' water to remove any residual formulation after which they were patted 
dry wi th a towel. The sites often showed puckering but this reverted to 
normal within half an hour. Occasionally erythema was present around the 
app l ication but this too disappeared within half an hour . 
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2 . 1.3 Reading of Results : 
Three independent observers were used to evaluate results in a double 
blind techni que. Blanching was determined at 7, 8, 10, 12, 14, 16, 18, 
24 and 28 hours after application which allowed the establishment of a 
bl anching profile. 
Standard l ighting by overhead fluorescent lamps Was used throughout the 
investigation. The arms were pl aced horizontally on a desk directly in 
front of the investigator. 
The averaged readings of all three observers were used to analyse the data . 
A typical blanching response ten hours after application utilizing a 
six hour occlusion time. 
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2.2 STATISTICAL EVALUATION 
86 Three methods were used to evaluate the results. 
Method 1 
Number of Sites Exhibiting Blanching: 
This method involved a simple yes-no determination of whether or not 
vasoconstriction was present at each application site. These data 
we.re reported in terms of total number of sites responding to a given 
formulation. 
Method 2 
Intensity of Vasoconstriction: 
A visual determination of the degree of vasoconstriction produced at 
each site was made with t his method. An arbitrary response scale was 
defined as fOl lows: 
o No blanching. 
area of skin. 
Application site appeared identical to surrounding 
1 Faint pallor observed , clear outline of application square was not 
seen. 
2 Moderat e blanching, square outline of application si t e clearly visible. 
3 Intense pallor was observed over entire square of application site. 
Method 3 
Paired Comparison of Adjacent Application Sites: 
This method involved the direct comparison of different formulations 
applied as pairs. For each pair the following decision was required : 
(i) one site exhibited a greater degree of blanching ; 
(ii) both sites exhibited equal blanching; 
(iii) blanching was not observed at either site. 
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Blanching readings were terminated at 28 hours after application. 
However, in most Cases a response was still evident at this terminal 
reading and hence it was necessary to calculate a correction factor. 
and 
Where (R)28hr is the response at the 28 hour reading time 
ke is the elimination constant 
The el imination constant is determined from the s lope of the terminal 
24 hour - 28 hour portion of the semi-log plot of % TPS vs. time. 128 ,1 29 
The area from the correction fac tor was added to the area obtained from 
the trapezoidal rule to yield a corrected AUC value . 
The disadvantage of ca lculating the correction fac tor in this manner is 
that the el imination constant is determined f rom the s lope between the 
24 hour and 28 hour readings . Thus only two points are used to determine 
this slope and any minor error wil l significantl y affect the correction 
factor . 
As an example of this, if the 24 hour % TPS reading remains constant and 
the 28 hour % TPS reading decreases successively by 0 ,1 units then the 
change in area under the curve and corrected area unde!" the curve, 
determined by this change in slope, will be a s listed bel ow . 
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% TPS 24 hour % TPS 28 hour Area under Corrected area the curve under the curve 
1 0 , 9 3 , 8 37 , 97 
1 0 ,8 3 , 6 17,94 
1 0,7 3 ,4 11, 25 
1 0,6 3,2 7 ,90 
1 0,5 3,0 5 , 89 
1 0 ,4 2 , 8 4,55 
1 0 , 3 2,6 3 , 60 
1 0,2 2,4 2 , 90 
1 0 ,1 2,2 2 , 37 
It can be seen from the above Table that the possible error in the 
corrected area under the curve value is greatest when the difference 
between the 24 hour % TPS reading and the 28 hour % TPS reading i s 
small. 
It would be statistically more correct to extend the observation times 
to include at l east one more reading after the 28 hour reading time , and 
to determine the slope of the extended portion by linear regression . 
This , however, i s not practica l as it becomes extremely difficult to 
assess the blanching response after the 28 hour period . 
- 31 -
3. DISCUSSION 
3.1 THE ASSESSMENT OF VARIABLES AFFECTING THE BLANCHING ABILITY OF 
FORMULATED PRODUCTS 
48 Since its inception in 1962 , the McKenzie/Stoughton blanching assay has 
undergone many modifications in an attempt to make it a precise , reproducibl e 
and quantitative method of analysis for topical corticosteroids and formulated 
products. The parameters which are subject to most variation are : 
(i) Measurement of the blanching response. 
(ii) The mass of formulated product applied to each test site . 
(iii) The length of occlusion time. 
Of these parameters, th'e assessment of the blanching response has been 
subjected to most modifications. This has been discussed elsewhere. (See 
sections 1.2.1 and 1. 2 . 3 . ) 
The application of reproduci ble amounts of formulated product to the test 
site is extremely difficult. 88 Woodford noted that for Betnovate cream 
and ointment a variation in mass of 3 to 8 mg did not significantly affect 
the degree of pallor produced. 130 Polano et al. found that corticosteroids 
in amounts as different as 8 to 55 mg in 0,25% hydrocortisone butyrate 
cream did not affect the rate of penetration through cadaver epidermis. 
57 . . . . f f . . f Baker and Sa ttar uSlng alcohollc di lutlons 0 our new derl vatl ves 0 
corticosterone demonstrated that different concentrations produced differing 
degrees of blanching. It is possible that a saturated state could arise, 
i.e. , the amount of steroid diffusing from the base could be greater than 
the amount which can passively diffuse through the skin. 
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50 
McKenzie demonstrated that for a number of different steroids dissolved 
in 95% alcohol an occlusion time of 16 hours increased the absorption of 
the steroids by one hundred fold over the unoccluded mode. It is not 
known whether the blanching response will increase proportionall y wi th 
an increase in occlusion time or whether there is an optimum time above 
which no further increase in blanching response will be produced. 
It Was therefore decided to conduct an in depth study on the effect of 
the amount of formulated product applied to the test site and the effect 
of occlusion time on the degree of blanching observed . 
The formulation chosen for these experiments was Bet novate cream (0 ,1 % beta-
methasone 17-valerate). Although the results obtained and conclusions 
drawn can only apply to this preparation it is reasonable to suggest that 
similar trends would be obtained with other similar topical corticosteroid 
preparations. 
3.1.1 The Effect of the Amount of Formul ated Product Applied to the Test 
Si te. 
For this trial 11 volunteers were used. Both forearms were masked to 
produce 12 application sites per arm. Betnovate cream was purchased 
from a local pharmacy and the first gram of cream was discarded. 90 To 
each discrete site , 2 , 3, 4 or 5 seven mm stripes of cream were applied 
in a random manner. Both arms were occluded for 6 hours. 
Using differential weighings it was found that the mass of cream applied 
to each application site varied. Four stripes of Betnovate cream have 
an average mass of 3,03 mg. Forty weighings were performed and 
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the standard deviation was calculated to be 0,71 mg. This is high and 
for this reason a large number of sites (66) were used for each different 
mass applied. 
Fig. 1 depicts the blanching profiles obtained f or each different mass 
applied and Table 1 lists the results of the statistical analyses. 
Statistically significant differences were obtained between 2 and 3 
stripes and 3 and 4 stripes, but very few significant differences were 
observed between 4 and 5 stripes. There is an increase in blanching 
wi th an increase in the amount of formulation applied to the skin. As 
can be seen from the AUC values there is a decrease in the difference 
between successive values with an increase in concentration. This 
suggests that it could be possible to determine the concentration limit 
in terms of blanching response. 
mounted. 
Consequently an additional trial was 
In the second trial 11 volunteers were also used . To each discrete site, 
5, 6, 7 and 8 seven mm stripes of cream were applied in a random manner. 
The use of 5 stripes allowed for intercompa.rison between this trial and 
the previous one. . Fig • . 2 depicts the b lanching profiles obtained for 
each different masS applied. 
A few statistically significant differences were noted between 5 and 6 
stripes but no differences were observed between 6 and 7 and 8 stripes. 
From the results of these two trials it can be seen that an increase in 
the amount of preparation applied to the skin causes an increase in the 
blanching response, but there appears to be a maximum amount of cream 
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TABLE 1 
TWO STRIPES 
TIME(HOURS) 
RESPONSE 7 8 10 12 14 16 18 24 28 
0 103 70 36 30 40 53 82 160 168 
1 63 91 98 89 78 103 92 20 12 
2 11 13 42 56 61 22 6 0 0 
3 3 6 4 5 1 2 0 0 0 
TOTAL 94 135 194 216 203 153 104 20 12 
TPS 540 540 540 540 540 540 540 540 540 
% TPS 17,4 25 ,0 35 , 9 40 , 0 37 , 6 28,3 19 , 3 3,7 2, 2 
THREE STRIPES 
RESPONSE 7 8 10 12 14 16 18 24 28 
0 84 49 20 10 16 37 64 137 .152 
1 76 107 80 80 103 111 107 43 28 
2 18 20 71 83 56 30 9 0 0 
3 2 4 9 7 5 2 0 0 0 
TOTAL 118 159 249 267 230 177 125 43 28 
TPS 540 540 540 540 540 540 540 540 540 
% TPS 21 , 9 29,4 46,1 49,4 42,6 32,8 23 , 2 8,0 5 , 2 
FOUR STRIPES 
RESPONSE 7 8 10 12 14 16 18 24 28 
0 69 47 20 9 16 27 45 144 156 
1 86 96 59 60 71 106 118 36 24 
2 21 29 92 96 85 45 17 0 0 
3 4 8 9 15 8 2 0 0 0 
TOTAL 140 178 270 297 265 202 152 36 24 
TPS 540 540 540 540 540 540 540 540 540 
% TPS 25,9 33,0 50 ,0 55 , 0 49,1 37 , 4 28,2 6,7 4,4 
•• ••• Table 1 continued/ 
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TABLE 1 continued/ 
FIVE STRIPES 
TIME(HOURS) 
RESPONSE 7 8 10 12 14 16 18 24 28 
0 56 38 10 9 14 30 46 147 158 
1 91 99 59 48 75 98 11 4 32 22 
2 28 35 94 104 82 48 20 1 0 
3 5 8 17 19 9 4 0 0 0 
TOTAL 162 193 298 313 266 206 154 34 22 
TPS 540 540 540 540 540 540 540 540 540 
% TPS 30 , 0 35 , 7 55 , 2 58 , 0 49 , 3 38,2 28,5 6 , 3 4 ,1 
AREA UNDER THE CURVE VALUES 
UNCORREX::T ED AREA CORREX::T ED 
TWO STRIPES 490 , 80 507 , 7 
THREE STRIPES 616 , 70 664 , 98 
FOUR STRIPES 691 ,20 733 , 06 
FIVE STRIPES 728,65 766 , 83 
••• •• Table 1 continued/ 
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Table 1 continued/ 
TABLE USED IN CALCULATING ;:1::.2 VALUES FOR INTENSITY OF BLANCHING STATISTI CAL 
MEIHOD . 
TWO STRIPES VS. THREE STRIPES 
TIME(HOURS) 
7 8 10 12 14 16 18 24 
0 103 84 70 49 36 20 30 10 40 16 53 37 82 64 160 137 
1 63 76 91 107 98 80 89 80 78 103 103 111 92 107 20 43 
2 11 18 13 20 42 71 56 83 61 56 22 30 6 9 0 0 
3 3 2 6 4 4 9 5 7 1 5 2 2 0 0 0 0 
'X. 2 VALUE 5 , 04 6 , 88 15 , 76 16 , 06 16 , 62 4,37 3 , 95 10 ,1 8 
THREE STRIPES VS . FOUR STRIPES 
7 8 10 12 14 16 18 24 
0 84 69 49 47 20 20 10 9 16 16 37 27 64 45 137 144 
1 76 86 107 96 80 59 80 60 103 71 111 106 107 11 8 43 36 
2 18 21 20 29 71 92 83 96 56 85 30 45 9 17 0 0 
3 2 4 4 8 9 9 7 15 5 8 2 2 0 0 0 0 
X 2 VALUE 2,99 3 , 62 5 , 88 6 , 76 12 , 54 4 , 68 6 , 31 0 , 79 
FOUR STRIPES VS. TWO STRIPES 
7 8 10 12 14 16 18 24 
0 69 103 47 70 2C 36 9 30 16 40 27 53 45 82 144 160 
1 86 63 96 91 59 98 60 89 71 78 106 103 11 8 92 36 20 
2 21 11 29 13 92 42 96 56 85 61 45 22 17 6 0 0 
3 4 3 8 6 9 4 15 5 8 1 2 2 0 0 0 0 
"X 2 VALUE 13 , 54 11, 04 34 , 84 32 , 48 20 , 00 16 , 39 19,26 5 , 41 
•• ••• Table 1 continued/ 
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Table 1 continued/ 
TABLE USEJ) IN CALCULATING -x3 VALUES FOR INTENSITY OF BLANCHING STATISTICAL 
METHOD (c ont inu ed) . 
FOUR STRIPES VS . FIVE STRI PES 
TIME(HOURS) 
7 8 10 12 14 16 18 24 
0 69 56 47 38 20 10 9 9 16 14 27 30 45 46 144 147 
1 86 91 96 99 59 59 60 48 71 75 106 98 11 8 11 4 36 32 
2 21 28 29 35 92 94 96 104 85 82 45 48 17 20 0 1 
3 4 5 8 8 9 17 15 19 8 9 2 4 0 0 0 0 
-;t2 VALUE 2 , 60 1, 56 5 , 81 2 ,1 2 0 , 36 1, 24 0 , 32 1, 27 
FIVE STRIPES VS . TWO STRIPES 
7 8 10 12 14 16 18 24 
0 56 103 38 70 10 36 9 39 14 40 30 53 46 82 147 160 
1 91 63 99 91 59 98 48 89 75 78 98 103 11 4 92 32 20 
2 28 11 35 13 94 42 104 56 82 61 48 22 20 6 1 0 
3 5 3 8 6 17 4 19 5 9 1 4 2 0 0 0 0 
)(.2 VALUE 26 , 89 20 ,1 9 52 , 31 46 ,1 4 22 , 06 16 , 82 20 , 01 4 , 32 
FIVE STRIPES VS. THREE STRIPES 
7 8 10 '12 14 16 18 24 
0 56 84 38 49 10 20 9 10 14 16 30 37 46 64 147 137 
1 91 76 99 107 59 80 48 80 75 103 98 111 114 107 32 43 
2 28 18 35 20 94 71 104 83 82 56 48 30 20 9 1 0 
3 5 2 8 4 17 9 19 7 9 5 4 2 0 0 0 0 
-x..2 VALUE 10,41 7 ,1 3 12 ,1 7 15 , 95 10, 58 6 , 36 7 , 34 2 , 97 
28 
156 15· 
24 2: 
0 ( 
0 ( 
0 , 1C 
28 
158 168 
22 12 
0 0 
0 0 
3 , 25 
28 
158 152 
22 28 
0 0 
0 0 
0 , 84 
••••• Tabl e 1 continued/ 
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Table 1 cor:tinued/ 
TABLE US ED IN CALCULATING -xl VALUES FOR YESjNO STATISTICAL MEl'HOD. 
TWO STRIPES VS. THREE STRIPES 
TIME(HOURS) 
7 8 10 12 14 16 18 24 28 
YES 77 96 110 131 144 160 150 170 140 164 127 143 98 116 20 43 12 28 
NO 103 84 70 49 36 20 30 10 40 16 53 37 82 64 160 137 168 152 
1(2 VALUE 3 , 61 5,02 4 , 76 10 ,15 11, 19 3 , 33 0 , 37 9,31 6,3 3 
THREE STRIPES VS . FOUR STRIPES 
7 8 10 12 14 16 18 24 28 
YES 96 111 131 133 160 160 170 171 164 164 143 153 11 6 135 43 36 28 24 
NO 84 69 49 47 20 20 10 9 16 16 37 27 64 45 137 144 152 156 
X VALUE 2,23 0 , 01 0,03 0 , 00 0 , 03 1, 54 4 , 26 0 , 58 0 , 201 
FOUR STRIPES VS. TWO STRIPES 
7 8 10 12 14 16 18 24 28 
YES 111 77 133 11 0 160 144 171 150 164 140 153 127 13 5 98 36 20 24 12 
NO 'c b, 103 47 70 20 36 9 30 16 40 27 53 45 82 144 160 156 168 
")(2 VALUE 12 ,1 2 6 ,1 3 4 , 76 11 , 50 11 ,19 10,04 15 , 77 4,76 3, 74 
FOUR STRIPES VS . FIVE STRIPES 
7 8 10 12 14 16 18 24 28 
YES 11 1 124 133 142 160 170 171 171 164 166 153 150 135 134 36 33 24 32 
NO 69 56 47 38 20 10 9 9 16 14 27 30 45 46 144 147 156 158 
~ VALUE 1,77 0,99 2 , 95 0,06 0,04 0 , 08 0,00 0,07 0,63 
••••• Table 1 continued/ 
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Table 1 continued/ 
TABLE USED IN CALCULATING ~ VALUES FOR YES/NO STATISTICAL METHOD (continued). 
FIVE STRIPES VS. TWO STRIPES 
TIME(HOURS) 
7 8 10 12 14 16 18 24 28 
YES 124 77 142 110 170 144 171 150 166 140 150 127 134 98 33 20 32 12 
NO 56 103 38 70 10 36 9 30 14 40 30 53 46 82 147 160 158 168 
X VALUE 23 , 84 12,71 15 , 58 11 , 50 13 , 62 7,58 14,85 3, 19 8,19 
FIVE STRIPES VS. THREE STRIPES 
7 8 10 12 14 16 18 24 28 
YES 124 96 142 131 170 160 171 170 166 164 150 143 134 116 33 43 32 28 
NO 56 84 38 49 10 20 9 10 14 16 30 37 46 64 147 137 158 152 
,,2 VALUE 8,42 1 ,52 2,95 0,00 0,04 0 , 66 3,78 1,35 0,04 
•••••• Table 1 continued/ 
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Table 1 cont inued/ 
TABLE USED IN CALCULATING J(2 VALUES FOR PAIRED COMPARISON STATISTICAL 
METHOD. 
TWO STRIPES VS . THREE STRI PES 
TIME(HOURS) 
7 8 10 12 14 16 18 24 28 
° 
45 17 7 1 5 14 25 89 96 
= 8 3 2 4 4 10 5 1 
° <. 45 65 85 76 74 59 50 23 17 
> 22 35 26 39 37 37 40 7 7 
2 VALUE 7 , 22 8 ,41 30 , 31 11 , 27 11 , 68 4 , 59 0 , 90 7, 50 3 , 38 ): 
THREE STRIPES VS. FOUR STRIPES 
7 8 10 12 14 16 18 24 28 
° 
29 14 6 3 4 7 11 81 96 
= 7 7 3 5 7 11 10 2 2 
< 46 49 59 54 57 56 55 17 8 
> 38 50 52 58 52 46 44 20 14 
-1.. VALUE 0 , 58 0 , 00 0 , 32 0 , 08 0 ,1 5 0 , 79 1 , 01 0 ,11 1 ,1 4 
FOUR STRIPES VS. TWO STRIPES 
7 8 10 12 14 16 18 24 28 
° 
33 16 6 2 5 10 22 93 104 
= 6 5 8 7 6 7 11 1 
° .( 23 31 29 42 33 30 32 8 9 
> 58 68 77 69 76 73 55 18 7 
2 VALUE 14 , 27 13 , 09 20 , 84 6 , 09 16 ,1 8 17 , 13 5,56 3 , 11 0 , 06 
-x. 
••••• Table 1 continued/ 
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Table 1 continued/ 
TABLE USED IN CALCULATING )(2 VALUES FOR PAIRED COMPARISON STATISTICAL 
METHOD (continued). 
FOUR STRIPES VS . FIVE STRIPES 
TIME(HOURS) 
7 8 10 12 14 16 18 24 28 
0 22 10 4 0 1 8 18 91 108 
= 10 10 7 7 11 7 9 3 1 
<: 45 57 67 63 55 53 37 11 4 
> 43 43 42 50 53 52 56 15 7 
2 VALUE 0,01 1, 69 5,28 1, 27 0 , 09 0,00 3 , 48 0,35 0,36 
"X. 
FIVE STRIPES VS. TWO STRIPES 
7 8 10 12 14 16 18 24 28 
0 27 15 3 1 3 13 19 88 102 
= 7 5 5 3 13 13 7 1 0 
.( 14 17 16 23 29 24 32 10 9 
> 72 83 96 93 75 70 62 21 9 
-l VALUE 37 , 78 42,25 55 , 72 41, 04 19 ,47 21 , 54 8 , 95 3 ,23 0,05 
FI VE STRIPES VS. THREE STRIPES 
7 8 10 12 14 16 18 24 28 
0 23 11 1 1 2 10 14 80 95 
= 6 9 5 7 5 7 13 3 1 
< 26 35 35 38 46 40 37 18 9 
> 65 65 79 4 67 63 56 19 15 
i VALUE 15,87 8 ,41 16,22 25,93 3,54 4 , 70 3 , 48 0,00 1,04 
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above which no further blanching response is observed. There are a 
number of reasons which could account for this observation. 
Reference to figs. 1 and 2 indicates that the preparation being tested 
has not caused the maximum possible blanching. It may be that the response 
observed f or 6, 7 and 8 stripes is a maximum response for betamethasone 
17-valerate and no matter how much more of the steroid is applied to the 
skin no further increase in blanching would be produced. It is presumed 
that only a certain amount of betamethasone 17-valerate Can passively 
diffuse through the skin, no matter how much ster oid is being released 
from the cream base. Alternatively it may be possible that more steroid 
penetrates through the skin than there are receptor sites available at 
the test site. 
The maximum response observed may a lso be due to the thickness of the 
layer of cream applied to the test site. All the sites are the same 
2 
area, 7 nun • The more cream applied, the thicker the layer but the 
area in contact with the skin remains the same . The steroid wil l only 
be able to diffuse through a certain amount of cream and it may be that 
once the thickness of the layer reaches a certain limit that the steroid 
is physically too fa r removed from the skin for it to be absorbed at all. 
No log dose response curve has been drawn as, although the amount applied 
is related to the dose , the actual concentration at the receptor site 
is not known. 
3.1.2 The Effect of Occlusion Time on the Blanching Ability of Formulated 
Products 
Occlusion of topical steroid preparations with a non-porous plastic film 
- 45 -
has been used for a number of years as a means of increasing the absorption 
of topical corticosteroids through the skin. 
No in-depth study has been reported, however) to investigate the effect 
of occlusion time on response , or to de termine how cri tical the period 
of occlusion may be. For this trial 17 volunteers were used . Both 
forearms were masked to produce 12 application si tes per arm . The 
standard mass of Betnovate cream was applied to each site after which 
all sites were occluded. The occluding films were removed in a random 
manner 2, 4, 6 and 8 hours after application. 
The results of this trial are depicted graphically in fig. 3. X 2 
analyses of the result demonstrated significant differences between all 
occlusion times. The AUC values tended to suggest that, as in the case 
of increasing the concentration with respect to response, increasing the 
occlusion further may result in the achievement of a plateau. 
In order to confirm this, a fur ther trial was undertaken. In this trial 
16 volunteers were used. The 12 demarcated application sites were occluded 
for 8, 10 and 12 hours, the order of which had previously been randomised. 
The 8 hour occlusion time allowed intercomparison between this and the 
previous trial. 
Graphical representation of the results are shown in fig. 4. X 2 
analyses showed a few statistically signif icant differenc es between the 8 
and 10 hour occlusion times but there were no di fferences between the 10 
and 12 hour occlusion times. The differences between successive occlusion 
times decrease with increase in occlusion time, which suggests that a 
plateau was being attained, but the actual AUC values increased with 
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increase in occlusion time. This corresponding increase, which was not 
proportional to increased occlusion time suggests that an absolute maximum 
response had not been attained with the 12 hour occlusion time . 
From f igs. 3 and 4 it can be seen that the response increases with an 
increase in occlusion time, but above a certain period of occlusion no 
further increase in response is obtained. 
This plateau effect could be due to maximum absorption of the steroid 
present , i.e. , unless the concentration of steroid per si te is increased 
there can be no further increase in response. If this plateau is due 
to,too Iowa concentration of steroid, it would r equire additional trials 
to determine the period of occlusion above which no further response is 
observed . An increased mass of preparation would have to be applied to 
the site and occlusion times of 10 and 12 hours used. If an increased 
response is obtained using these larger masses then it can be assumed 
that the plateau depicted in f i g . 4 is due to the concentration of 
steroid. If on the other hand no increase in response is observed , 
then it can be assumed that the plateau is due to other paramet ers. 
One expl anation for a ttaining a plateau effect is that the steroid present 
has reached a maximum blanching effect and t hat no matter how much t he 
concentration is increased no greater response will result . 
Another possible explanation for the plateau effect is that above a 
certain occlusion time there is maximum hydration of the s tratum corneum 
and thus, maximum absorption of the steroid . 
- 49 -
Because of the results obtained from these two trials it was decided to 
use a 6 hour occlusion time in all subsequent trials. The reasons f or 
this are that this period allows excellent discrimination between 
different preparations. Also t since most experimental work in this 
fie l d makes use of a 6 hour occlusion time , it was felt that standardisation 
would be an advantage. Six hour occlusion time was found to be convenient 
and did not subject the volunteers to undue discomfort. Because of the 
increase in response with longer occlusion times in all subsequent trials 
a 6 hour period of occlusion was rigi dly adhered to. 
3.2 THE IN VIVO ASSESSMENT OF EXT EMPORANEOUS DILUTIONS OF TOPICAL 
~
CORTICOSTEROID PREPARATIONS 
3.2 .1 Introduction 
Considerable time, effort and money is spent in the development of vehicles 
for topical steroid preparations. These should provide the optimum 
rel ease characteristics f or any particular steroid. The vehicles are 
extremely sophisticated and any extemporaneous dilution of these may 
therefore alter thei r release characteristics. Manufacturers therefore 
continually warn about the possible dange~s of extemporaneous di lution 
of their commercially available topical steroid formul ations. Despi te 
these warnings, topical steroid preparations are frequently diluted with 
a variety of bases in an attempt to either decrease the potency of the 
formulation or to alter the release characteristics of the vehicle. 
Very little work has, however, been carried out on these di luted 
formulations and thus it is not known to what extent the potency lS 
affected or to what extent the release characteristics of the original 
base i s affected. 
• 
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It was therefore decided , to investigate the bioavailability of extemporaneously 
diluted topical steroid preparations at regular inteeval s over a prolonged 
period of time. 
For this study to be of practical use it was necessary to determine which 
commercially avai l able topical steroid preparations wer e most often diluted , 
which bases were most commonly used as the diluting media and to what 
extent the commercial products were generally diluted . In order to 
ascertain the above information it was necessary to conduct a small survey 
at the local pharmacies. The results of the survey showed that both 
Betnovate and Synalar creams were those preparations most commonly di luted , 
and the bases which were used to dilute these preparations were,Emu l sifying 
Ointment B.P. ; Aqueous Cream B.P .; BU£fered Cream B. P . C. ; EA5 cream 
and Ultrabase . These bases were most commonly used to di lute Betnovate 
and Synalar creams to 50% of their original strength. As a hal f strength 
Betnovate cream was commercially available and as we had the placebo 
Betnovate base it was also dec ided to include the commer ciall y available 
preparation and an extemporaneously prepared 50% dilution of Betnovate 
cream with the plac ebo base . 
Unfortunately it was not possible to obtain a commercially prepared 
half strength Synalar cream , but as Synadone (0,01% fluocinolone acetonide) 
and a small quantity of Synalar placebo cream base was available , from 
which a 50% extemporaneous formulation could be pr epared, a single 
assessment of each was carried out . 
3 . 2 .2 Preparat ion of Extemporaneous Dilutions 
Conditions in a pharmacy were simulated so that the study would have 
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practical application . Therefore the Betnovate and Synalar creams as 
well as all the bases apart from the Buffered Cream B.P .C. were purchased 
from a local pharmacy. No manufacturer's samples were used. Buffered 
Cream B.P.C. has a shelf life of 1 month,thus manufacturers do not find 
it a viable proposition to produce the cream. 
prepared the day prior to use. 
The cream was therefore 
Exactly equal amounts (150 g) of the corticosteroid formulation and the 
diluting bases were weighed out on a Sartorious 2 figure top loading 
balance. The vehicles were then thor oughly mixed on an ointment slab 
after which the resultant preparations were placed in clear glass ointment 
jars and tightly sealed. Clear glass jars were used as extempor aneously 
prepared corticosteroid preparations are gene~ally dispensed from pharmacies 
in these containers. 
Within 12 hours of manufacture these freshly prepared formulations were 
assessed in vivo for biological availability. 
3.2.3 50% Preparations Studied Routinely 
Preparation Abbreviation 
Betnovate / Aqueous Cream B.P. a 
Betnovate / Buffered Cream B. P.C. b 
Betnovate / E45 cream c 
Betnovate / Ultrabase d 
Betnovate / Emulsifying Ointment B.P. e 
Betnovate / Betnovate placebo base f 
Betnovate Half Strength g 
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Preparation Abbreviation 
Synalar / Aqueous Cream B.P. A 
Synalar / Buffered Cream B.P.C. B 
Synalar / E45 cream C 
Synalar / UI trabase D 
Synalar / Emulsifying Ointment B.P. E 
3.2.4 Preliminary Investigation 
In each assessment either Betnovate or Synalar creams were used as well 
as the extemporaneously prepared creams to allow inter comparison between 
successive trials. 
In the first assessment, Betnovate cream and 4 dilution s of Betnovate 
(a, d , f , g) were tested. Twelve volunteers with both forearms masked 
to produce 12 test sites per arm were used. The standard mass of 
preparation was applied to each test site in a random manner after which 
one arm was occluded, the other left unoccluded,but protected with a 
cardboard frame to prevent spreading. 
The results are depicted graphically in figs. 5 and 6. It can be seen 
from the blanching profiles of the unoccluded study, fig . 5, that the 
results are totally unsuitable for statistical analyses as it is not 
possible to visually discriminate between the test preparations du e to the 
poor blanching response observed. 
It was therefore decided that in all subsequent in vivo assessments of 
50% extemporaneous dilutions of topical steroid preparations only the 
occluded mode would be used. 
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3 . 2 . 5 The in vivo Assessment of Betnovate and Betnovate/Dilutions 
The above trial was repeated using freshly prepared di lutions (a, d , f , g). 
The results of this trial as well as the remainder of t he fresh l y prepared 
dilutions (b, c , e) are depicted i n figs . 7 and 8 . 
In a ll of the above mentioned trials, between 10 and 12 volunteer s were 
used, 12 discrete sites were demarcated on both forearms and both arms 
were occluded for a period of exactly 6 hours . 
The results of the Betnovate di lution studies demonst ra ted no statistically 
significant differences between any of the hal f strength preparations . 
I n one trial (fig . 7 ) there are statistically significant differenc es 
between the hal f strength preparations and Betnovate cream. In the 
other trial (fig . 8) no statistically significant differences were 
demonstrated . It is interesting to note that the response obtained 
from the half strength preparations as measured by AUC values are no t 
v ery much less than Betnovate in fig . 7, but significantly different 
in fig . 8 . This difference, however , is not linearly related to the 
concentration of corticosteroid present. 
The diluted preparations were stored at room temperature on open shelves 
that were neither exposed to, nor protected from, excess light. 
were thus simi lar to those found in mos t pharmacies. 
Conditions 
Approximately one month after dilution , t he preparations were thor ou ghly 
mixed and then tested in vivo again for bl anching activity . Where 
possible , the same volunteers as those used to assess the freshly prepared 
di lutions were used to assess the same preparations. 
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The results for the two trials are depicted graphical l y in figs. 9 and 
10. 
2 ~ analyses of the results depicted in fig. 9 generally show very few 
statistically significant differences between the vari ous preparations. 
The intensity of blanching of the Betnovate/Aqueous Cream formulation is 
greater than that of Betnovate. Betnovate , however , has a slightly l onger 
response, giving it an AUC value marginally greater than Betnovate/AqueouS 
Cream, which in turn is supe:cior to the other hal f strength formulations 
(d , f, g). It could be suggested that this superior response is a 
concentration effect but this seems unlikely as a large number of si tes 
(58) were used for each prepar ation. 
~2 analyses of the results depicted in fig. 10 show no statistically 
significant differences between Betnovate/Buffered Cream and Betnovate/ 
Emulsifying Ointment which may be expected because of the similarity 
between Buffered Cream B.P.C. and Emulsifying Ointment B.P. There are 
a few statistical differences between the various blanching profiles , 
but these differences are due mainly to a shift to the l eft of the 
Betnovate/E45 blanching profile. Despite this shift to the left , AUC 
val ues for the 3 half strength preparations (b , c , e) ar e very simi l ar 
although less than the AUC value for Betnovate. This shift to the left 
suggests that Betnovate/E45 produces a slightly greater initial response 
with a fas t er onset of blanching activity, bu t once the maximum intensity 
of blanching has been reached the amount of blanching produced by Betnovate, 
Betnovate/E45 decreases at a greater rate than the blanching effect of 
Betnovate/Emulsifying Ointment and Betnovate/Buffered Cream. It therefore 
appears that the Betnovate/E45 fO.rmulation allows a faster rat e qf . .rel ease 
and subsequent removal of betamethasone 17-valerate f rom the site of action. 
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Comparing the r esults of these two trials with the results obtained from 
the previously described data (figs. 7 and 8) there appears to be very 
little change in the potency and release characteristics of the preparations. 
No physical tests or assays were conducted on the preparations after one 
month, but a visual inspection of them shmled no physical 
change. 
The Betnovate di lutions were tested in vivo for blanching activity again 
3 months after manufacture. The results are depicted graphically in 
figs . 11 and 12. 2 ~ analyses of the results depicted in fig. 11 show 
virtually no statistically significant differences between any of the 
formulations (a, d , f, g). Area under the curve values were likewise 
very simi lar. 
)(2 analyses of the results depic ted in fig. 12 show statistically 
significant differences between Betnovate and Betnovate/Emulsifying 
Ointment at most reading times in favour of the former and a few 
significant differences between Betnovate/E45 and Betnovate in favour 
of the la tter. 
It is interesting to note the similarity between the relative AUC values 
of Betnovate/Aqueous Cream and Betnovate/Buffered Cream, and their 
superiority compared to Betnovate/Emulsifying Ointment. Aqueous Cream 
B.P. and Buffered Cream B.P.C. both contain the same amount of water, 
whereas Emulsifying Ointment B.P. is formulated without water. It 
therefore seems possible that the amount of water present may effect 
the blanching response, possibly by increasing the hydration of the 
stratum corneum which in turn allows better penetration of the steroid. 
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The Betnovate dilutions were again tested in vivo for blanching activity 
9 months after manufacture. The results are depicted graphical ly in 
figs. 13 and 14. ~ 2 analyses of the results depicted in fig. 13 show 
statistically significant differences between the extemporaneously prepared 
Betnovate/Betnovate Base and Betnovate . Area under the curve values for 
all half strength preparations (a, d , f , g) are larger than the 
corresponding AUC value for Betnovate cream • 
. ~2 analyses of the results depicted in fig. 14 show very few statistically 
significant differences between any of the preparations (b , c, e). 
Comparison of the results of all the in vivo assessments of Betnovate 
dilutions over a period of 9 months show very little change in the potency 
and release characteristics of the preparations. Visually there appears 
to be no change in the physical properties of the pr eparations. 
Six months after manufacture all the Betnovat e diluti ons were 
assayed by HPLC (See section 4) and were found to be within B. P. limits . 
However , when these dilut i ons were again analysed 14 months after 
manufacture , it seemed that some of the betamethasone 17- valerate had 
been converted to the 21-valerate isomer. (See section 4.5). 
Because of this conversion it was decided to again assess the blanching 
ability of the Betnovate/E45 dilution. The results of this trial are 
depicted in fig. 15. 
~ 2 analyses of the blanching profiles depicted in fig. 15 demonstrated 
statisticall y significant differences between Betnovate and Betnovate/E45 
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at most reading times . These differences are due mainly to the lower 
intensity of blanching and subsequent faster decrease in the blanching 
effect of Betnovate/E45 compared to Betnovate. The AUC values of 
Betnovate/E45 is however, lower than that of Betnovate , but the difference 
between the 2 AUC values i s not as large as one would expect considering 
that the concentration of betamethasone 17- val erate in Betnovate/E45 is 
approximately one quarter (see Section 4 . 5) of that of Betnovate and that 
the blanching ability of betamethasone 2 1-vale~ate is lower than that of 
53 betamethasone 17-val erate . 
3 . 2.6 The in vivo Assessment of Synalar Cream and Synalar Dilutions 
Graphical representation of the in vivo assessment of freshly prepared 
X 2 Synalar dilutions are shown in figs . 16 and 17. analyses of the 
results depicted in fig . 16 show no statistically significant differences 
amongst the half strength formulations (A, B, E) but statistica lly 
significant differences between the half strength formul ations and 
Synalar cream in favour of Synalar cream at the 10, 12 and 14 hour 
readings. 
~2 analyses of t he resul ts depicted in fig . 17 demonstrated equivalence 
between Synadone ( 0 , 01% f luocinolone acetonide ) and SynalarjUltrabase 
( 0 , 0125% fluoc inolone acetonide), but statistically significant di fferences 
were observed between Synadone and Synalar/E45 in favour of the latter and 
be t ween Synalar. and Synalar/E45 in favour of the former . 
The results of the ~ vivo assessment of the one month Synalar dilution 
s tudy are depicted in figs. 18 and 19. 
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jL2 analyses showed no statistically significant differences between 
the blanching profi les of Synalar and Synalar/Aqueous Cream , but a few 
differences were noted between Synalar and SynalarjBuffered Cream in 
favour of the latter and Synalar and synalar/Bnulsifying Ointment in 
favour of the former . 
The largest AUC value '''as obtained for Synalar /Buffered Cream. The value 
was considerably larger than the 2 relatively equal AUC values obtained 
from Synalar anc Synalar/Aqueous Cream and suggest a better re lease of 
fluoc inolone acetonide from Synalar/Buffered Cream than Synalar. This 
is somewhat a l arming in that the data implies that the fluocinolone 
acetonide is not efficiently rel eased from the commercially availabl e 
Synalar preparation . 
The smallest AUC value was obtained for Synalar/Bnulsifying Ointment. 
As in the case of the Betnovate dilution study it is suggested that the 
increased amount of water in both Aqueous Cream B.P. and Buffered Cream 
B. P. C. compared to Bnulsifying Ointment B. P. allows for a greater release 
rate and subsequent penetration of the corticosteroid from the cream 
preparations. 
During the investigation of the one month old dilutions , Synalar Forte 
(0,2% f l uocino l one acetonide) was included in a trial to observe the 
effect of an increased concentration on the b l anching r esponse of 
Synalar. X. 2 analyses of the results depicted in fig. 19 show 
statistically significant differences between Synalar and Synal ar 
Forte at all reading times in favour of t he latter . There were also 
statistically significant differenc es between Synalar and synalar/ 
Ultrabase and a few significant differences between Synalar and Synalar/E45 . 
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Comparing the blanching profiles of Synadone , Synalar and Synalar Forte , 
it appears that Synalar Forte not only produces an increase in intensity 
of blanching~ but also a much longer blanching response than both Synadone 
and Synalar . From this comparison it also appears that the conc ent ration 
of f luocinol one acetonide incorporated in Synalar cream may be lower than 
the concentration required to produce the maximum response . It is 
interesting to note that Synalar Forte , wh ich is 8 times more potent 
than Synalar , produces a response which is approximately 1,7 times greater 
than the r esponse of Synalar as measured by AUC values . It therefore 
appears that Syna l ar Forte produces maximum blanching, but that the 
concentration of f luocinolone acetonide in Synalar Forte is much greater 
than tha t required to produce this maximum blanching. Only by a di rect 
comparison of various amounts of Synalar For t e appli ed to the t est site 
coul d this suggestion be substantiated . 
Comparing the results of the freshly prepared Syna l ar dilution with those 
obtained one month after manufacture there appears to be very li ttle 
change in the bl anching a ctivity of the preparations . No physical tests 
or assays were performed on the preparations but visual ly the preparations 
appeared stable . 
The results of the in v i vo assessment of the 3 month ol d di lutions are 
depic t ed in figs . 20 and 21. Jl2 analyses of the results depicted in 
fig. 20 show no statistically significant differences between Synalar and 
synalar/Aqueous Cream, but a few statistically significant differences 
between Synalar and Synalar/Buffered Cream in favour of the l atter and 
statistically significant di fferences between Synalar and Synalar/ 
Emulsifying Ointment at mos t reading times in favour of Synalar . There 
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is a striking similari ty between these resul ts and the results depicted 
in fig. 18. In both trials Synalar/Buffered Cream produced the largest 
AUC value, Synalar artd Synalar/Aqueous cream very similar values and 
Synalar/Emulsifying Ointment the smallest value. 
X 2 analyses of the blanching profiles depicted in fig . 21 shows no 
statistically significant differences between Synalar/E45 and Synalar 
but a few differences between Synalar and Synalar;Ultrabase in favour 
of the former. It is interesting to note that the AUC value of Synalar/ 
E45 is slightly l ess than the AUC value of Synalar/Ultrabase, for in the 
two previous trials the AUC value of Synalar/E45 Was greater than that 
of Synalar;Ultrabase. This could suggest a decrease in the blanching 
activity of Synalar/E45. 
The Synalar di lutions were assessed again 9 months after manufacture. 
The results are depicted graphically in figs . 22 and 23. ~2 analyses 
of the bl anching profiles depicted in fig. 22 demonstrated equi va l ence 
between the blanching profiles of Synalar/Buffered Cream and Synalar/ 
Aqueous Cream although the AUC value of Synalar/Buffered Cream was larger 
than that of Synalar Aqueous Cream. There were s tatistically significant 
differences between Synalar and synalar/Buffered Cream a t most reading 
times in favour of the former and Synalar/Emulsifying Ointment and Synalar/ 
Aqueous Cream in favour of the latter at all reading times. 
~ 2 anal yses of the blanching profiles depicted in fig. 23 showed 
statistically significant differences between Synalar and Synalar/ 
Ultrabase a t all reading times and between Synalar/Ultrabase and 
Synalar/E45 at most reading times. Intercomparison of the results 
depicted in figs. 22 and 23 demonstra t ed that the smallest AUC value 
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was that produced by the Synalar/E45 dilution and that this AUC value 
was very much less than the AUC value produced by the Synalar ,iln trabase 
dilution . It can be noted that in the assessment of the freshly prepared 
Synalar di lutions (fig . 17), Synalar/E45 produced a much larger AUC 
value than Synalarjultrabase and that on closer examination of all 4 
in vivo assessments of synalar/E45 its AUC decreases successively over 
---
the 9 month tes ting period indicating a decrease in blanching activity . 
Because of the decrease in response of the Synalar/E45 dilution over the 
9 month testing period it was decided to assess the blanching ability of 
this dilution again, 14 mon ths after manufacture. 
The results of this trial are depic ted gr aphically in fig . 24. X 2 
analyses of the blanching profiles depicted in fig . 24 show statistically 
significant differences between Synalar and Synalar/E45 in favour of the 
former at all reading times. The blanching profile obtained for this 
dilution was i r regular with no gener al trend, similar to that normally 
obtained for placebo bases. 
It is apparent from the blanching profile and AUC value of the 14 month 
old Synalar/E45 dilution that this . preparation has vi r tually no blanching 
activity. This correlates with the analytical results in which no 
fluocinolone acetonide was found to be present in the 14 month old 
Synalar/E45 dilution. (See section 4.4). 
3.2 . 7 Conclusion 
From the blanching profiles of all the in vivo assessments of the 
Betnovate dilutions it is apparent that 50% extemporaneous dilution 
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of Betnovate cream produc ed a preparation of similar release character-
istics , blanching ability and potency to that of Betnovate cream. Barry 
noted similar results and suggested that there is a discrepancy between 
mathematical and physicochemical theory and dermatological practice. 131 
The diluting medium that had the greatest effect on Betnovate cream is 
E45 cream. .. f· 116 . . f The alkallnlty 0 thlS base lnduces the converSlon 0 
betamethasone 17-valerate to the isomer betamethasone 21-valerate. A 
possible mechanism for this conversion is shown in fig . 25 . 
It is not known how much of the 17-valerate will be conve~ ted to the 21 -
valerate as this will depend on the relative stabilities of the 2 isomers. 
If the stabi l ities of the 2 isomers are similar~then,because of the 2 
possible modes of opening of the cyclic intermediate by base attack, 
both isomers wi ll be expected to be present in similar amounts. 
From the in vivo assessment of the Betnovate/E45 dilution it appears 
that the conversion takes place between 9 and 14 months after manufacture, 
as 9 months after manufacture the area unde ' the blanching profile of 
Betnovate/E45 was larger than the corresponding value for Betnovate cream. 
However 5 months later t hi s value was found to be less than that of 
Betnovate, indicating a decrease in act i vity. It is known t hat beta-
methasone 21 - valerate has a lower blanching activity than betamethasone 
53 17-valerate. It is certain that this conversion does not take place 
within 6 mont hs as no betamethasone 21-valerate was found when the 
Betnovate dilutions were assayed by HPLC 6 months after manufacture. 
(see section 4.5) . 
... 0", 
o){ 00H / Jr-f-o 
17-valerate . 
... 0'1 If 0 H /6~ 
17-vaterate 
- 83 - FIGo 25 
~O~~ ~ 0"') \17 0 o>r--f---
21-valerate 
84 -
Because of the similarity between the responses of extemporaneously 
prepared 50% dilutions of Betnovate and commer cially available Betnovate 
cream it is economically advantageous to dilute Betnovate cream to this 
strength. No one base appears to be superior to the others. 
Unl ike Betnovate , where the nature of the di luting base has very little 
effect on the original preparation , the nature of the base used to di lute 
Synal ar cream to 50% of its original strength does affect the release and 
potency of the original preparation . 
It appears that di lution of Synalar c ream with Buffered Cream B. P.C. 
resul ts in a base of excel lent release characte-istics , as this 
preparation twice produced an AUC value greater than the corresponding 
value for Synalar (figs . 18 and 20). Dilution with Aqueous Cream B. P. 
a l so results in a base of good release characteristic s as can be seen 
from the assessments in which the AUC values of synalar!Aqueous Cream 
dilution were found to be similar to that of Synalar ful l strength 
(figs . 18 and 20) . 
Di l ution of Synalar cream with Ultrabase result s in a base of release 
c haracteristics similar to that of the commercial Synadone ( 0 , 01% fluocinolone 
acetonide). There appears to be no difference in the release 
of fluocinolone acetonide from ei ther Synadone or a 50% dilution of 
Synalar with Ultrabase. It is suspected that Ultrabase may contain 
propyl ene glycol and therefore , it may be possibl e that when Synalar 
cr eam is diluted with this base that the steroid is over - solubi l ised 
resulting in a dec rease in response . 
- 85 -
The use of E45 cream as the di luting medium initially produces a base 
f . .. b .. . . 116 o relatl vely good release characterlstlcs, ut Wl th tlme the alkahnl ty 
of E45 cream appears to alter the f luocinolone acetonide molecule resulting 
in a progressive decrease in blanching activity. 
The effect of alkali on the fluocinolone acetonide molecule is not known. 
It is however, highly unlikely that the steroid nucleus collapses under 
basic condi t ions. It is more probable that basic conditions may alter 
one or more of the side chains attached to this nucleus. Any modification 
of these side chains may alter the propert ies of fluocino l one acetonide 
accounting for a decrease in blanching activity. 
Modification of the side chain may resul t in a molecule of different 
pol arity to that of fluocinolone acetonide. Thus when a Synalar/E45 
dilution containing a converted molecule is assayed by HPLC (see section 
4 . 4) the modified mol ecule may have a different ret ention time t o t hat 
of fluocinol one acetonide , as was previously seen in the analysis of the 
aged Bet novate/E45 dilution (see section 4.5). It woul d therefore be 
possible for t his compound to ei ther remain on the column or to be 
eluted at the same rate as one of the suspected preservatives. This 
may result in the inability to assay or identify this compound. 
The progressive decrease in blanching acti vi ty of the Synalar /E45 dilution 
suggests that there may be a side chain modification which begins soon 
after preparation . 
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4. ANALYTICAL 
4.1 INTRODUCTION 
Steroids have been assayed by a number of different analytical methods. 
132 . 133 134 These methods include spectrophotometry, colorlmetry, , gas 
135 136 137 
chromatography , and other types of separations including high 
performance liquid chromatography (HPLC). 
Spectrophotometry and colorimetry both suffer from the same drawbacks 
in that the assay is non-specific for individual compounds and that 
there are many substances which interfere with the assay, especially 
. 138 139 in the case of colorlmetry. ' 
Paper chromatography, thin layer chromatography and column chromatography 
are generally appl icabl e for steroidal analysis as they are simple , 
., . d '" . f h . 140 lnexpenslve and do not reqUlre erlvltlzatlon 0 t e sterold. 
However, all these methods have the same inherent limitations with 
regard to speed of separation, ease of quanti tation and separation 
eff " 141 lCl.ency. 
Gas-liquid chromatography has become a popular method for steroidal analysis 
because of its speed, relative ease of quantitation and high resolution 
capabili ties. However, the method suffers from one major limitation in 
that many steroids have either a low volatili ty or are too thermally 
labile for direct chromatographic analysis. For these steroids, 
derivitization techniques are required, but , because of the complexity 
of the steroid molecule , it is often difficul t to obtain complete 
derivitization which is necessary for quantitation. 
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The analysis, separation and quantitation of pharmaceutical products 
by HPLC has been an extremely active area. 
I 'f ' d b H C f' db S" d D' hm 140 The ana YS1S 0 sterol s y PL was lrst reporte y 1991a an 1S an 
in 1970. They reported the separation of a number of structurally similar 
androgens, estrogens, progestins and adrenal corticosteroids employing a 
liquid ion exchange resin used as a reverse-phase packing. 142 Henry et al. 
reported on the separation of steroids using both partition and ion 
exchange packings. 
, ' 143-148 Since these two early reports, there have been numerous publlcat10ns 
using liquid chroma tography as a method of steroidal analysis and it has 
132 149 been recently recognised by the U.S.P. and National Formulary as 
the method of choice . Liquid chromatography is particularly well suited 
for analysis of extracts of steroids from tablets, ointments and creams, 
because of the very high degree of selectivity which enables separation 
of the steroid from the excipients. 
, I dB' t ,150 d t I 'I th d f t t' th Ba1 ey an rl ta1n use an ex reme y slmp e me 0 0 ex rac 1ng e 
steroid from the formulation. The formulation was partitioned between 
iso-octane and methanol. The steroid parti tioned in the methanol layer 
which was suitable for injection. 148 A recent publication makes use of 
an even simpler extraction by di spersing the formulation in hot water/ 
methanol or acetonitrile. These crude extracts significantly reduce 
the length of time required to assay a formulation, but tend to reduce 
the column life. 
Because of the speed , selectivity and simplicity of the procedure, HPLC 
was chosen as the method of analysis for this study. 
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4.2 THE ANALYTICAL SYSTEM 
A reverse phase system was chosen as it has wide application in the field 
of pharmaceutical analysis. 
The reverse phase system employs a non-polar stationary phase, usually 
composed of silica coated with high molecular weight hydrocarbons or 
substituted hydrocarbons. The mobile phase is generally a mixture of 
distilled water and miscible organic solvents e.g. methanol , acetonitrile, 
etc. 
The column employed in thi s study was the Varian Aerograph MicroPak CH-10 
column which was packed wi th porous silica (Li Chrosorb Si-60, a product 
of E. MERCK, Darmstadt .) of 10 micron average diameter, with a thin 
uniform layer of octadecylsilyl-groups chemically bonded to the silica 
through a stable siloxane bond. 
inner diameter of 0,21 cm. 
The column length was 25 em with an 
The column efficiency is approximately inversely proporti onal to the 
square of the flow veloci ty but by increasing the column temperature 
from 250 C to 500 C the efficiency of the column can be approximately 
doubled. 
4.3 THE METHOD OF QUANTITATION 
HPLC with concomitant automation used with the measurement and calculation 
procedure developed for gas chromatography is a highly accurate and 
precise analytical technique. 
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All preparations were assayed by this method. Use was made of the 
internal standard (I.S.) method of quantitation in which the sample peak 
of interest is quantitated relative to the internal standard peak. This 
method compensates for varying injections volumes and day to day instru-
mental changes. 
There are two basic ways of rel ating the analogue signal to concentration, 
namely peak height and peak area. 
The peak height ratios were compared to the peak area ratios for the same 
i njection. The date obtained from this comparison are listed below : 
Peak Height Samele Peak Area Sampl e 
Injection Number Peak Height I.5. Peak Area I.8. 
1 1,93 0,99 
2 2,00 1 ,11 
3 1,94 1, 07 
4 2,00 0,83 
5 1,91 0,95 
Average value 1.96 0,99 
Standard Deviat ion 0,0018 0 , 012 
The greater standard devia tion obtained from the peak area ratios is 
due to the difficulty encountered by the electronic integrator in 
determi ning when the s l ope changes sufficiently for it to start and 
stop calculating area under the peak. This difficulty is increased 
when broad peaks are encountered by the integrator . 
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It was therefore decided that in all subsequent quantitative assessments, 
peak height measurements would be used as the method of quantitation. 
4.4 TIl E HPLC ASSESSMENT OF FLUOCINOLONE ACEl'ONIDE IN SYNALAR FORMULATIONS 
Bailey and Brittain150 and COleman151 used a reverse phase C18 colulml as 
the stationary phase and methanol/water as the mobile phase in t he 
separation of fluocinolone acetonide from other extracted ingredients 
of Synalar cream. However, it was found that neither of these two sets 
of conditions were suitable fo r the analysis of the Synalar cream used 
in this study. The chromatogram of the Synalar cream used in this 
study showed an additional peak compared to the chromatogram of the 
" "1 " "150 d" k Synalar cream lllustrated by Bal ey and Brl ttaln an thlS pea 
overlapped with the fluocino lone acetonide peak. Changes in solvent 
concentration, flow rate, and pH were used in attempts to achieve 
separation, but without success. 
The use of the less polar solvent, ethanol effected separation of the 
fluocino lone acetonide but the resultant peak was broad and did not lend 
itself to quantitation. Changes of flow , pH and solvent as well as the 
addition of 1% tetrahydrofuran to the mobile phase did not improve the 
shape of the fluocino lone acetonide peak. However, by increasing the 
column temperature good separation was obtained with relatively narrow 
peaks. The increase in temperature, in addition, had the effect of 
reducing the assay time. It was found that the optimum column 
o temperature was 44 C. A temperature above this caused overlapping of 
the peaks and below this the peaks tended to broaden. 
Assay 
Reagents: 
(1) Water; Distilled 
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( 2) Methanol; Reagent Grade (Merck) 
(3) Iso-Octane; Reagent Grade (Merck) 
(4) Ethanol; Reagent Grade (Merck) 
(5) Norethisterone; Internal Standard. Accurately weigh out approximately 
0,12 g of norethisterone authentic specimen and transfer to a 50 ml 
volumetric f lask. Make up to volume wi th methanol. 
(6) Standard Preparation. Accurately weigh out approximately 2,5 mg of 
fluocinolone acetonide authentic specimen and transfer to a 50 ml 
volumetric flask. Add 1 ml internal standard solution and make up 
to volume with methanol. 
Procedure: 
(1) Accurately weigh out approximately 10 g of formulation into a 50 ml 
separa ting funnel. The formulation is placed into a 10 ml plastic 
disposable syringe immediately prior to the assay being performed. 
The syringe is weighed before and after extruding the formulation. 
(2) Add 15 ml of methanol. 
(3) With the aid of gentle heat and agitation dissolve the formulation 
in the methanol. 
(4) Add 50 ml of iso-octane. 
(5) Shake, allow to separate and run off the lower methanol layer into 
a second separating funnel. 
(6) To the iso-octane mixture in the firs t separating funnel , add 15 ml 
methanol. Shake , allow to separate and add the methanol layer to 
the second separating funnel . 
cause the l ayers to separate . 
Gentle heat may be necessary to 
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(7) Allow the combined methanol layer to stand for 15 minutes . 
achi eves further separation of the iso-octane layer. 
(8) Run the lower methanol layer into a 50 ml volumetric flask . 
( 9) Add 1 ml of the internal standard solution. 
(10) Make up to 50 ml with methanol . 
(11) Inject 2 ~l into the HPLC. 
Condi t ions for Use of HPLC 
Solvent: 33% Ethanol/67% Water. 
Column: CH-10 Micro Pax 25 cm x 2 mm (Varian). 
C 1 T 44oC. o umn emperature : 
Flow Rate: 50 ml/hr. 
Detector: 238 nm. 
SENSITIVITY. 
Calcul ations 
Detector 0,2 
C.D.S. 4 
Recorder 5 mv . 
This 
Linear regression was performed on the calibration plot of peak height 
ratio vs concentration of f luocinolone acetonide. 
The equation of this curve was found to be 
y = 0 , 0285 x 
with a correlation coefficient of r = 1, 01 . 
As an example , the data obtained from the analysis of Synalar/AqueoUs 
Cream is presented below. 
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Weight of Peak Height Peak Height Preparation Fluocinolone Acetonide Internal Standard Ratio Taken 
mm mm 
ASSAY 1 18 26 0,692 
10,81653 g 24 35 0,685 
25 36 0 , 694 
24 36 0 , 666 
ASSAY 2 32 43 0 ,744 
11 ,28620 g 29 40 0,725 
30 40 0 , 750 
27 36 0,750 
ASSAY 3 12 16 0 , 750 
11,31682 g 19 25 0 ,760 
22 30 0,733 
23 31 0 , 742 
ASSAY AVERAGE RATIO STANDARD DEVIATION COEFFICIENT OF % PURITY VARIATION 
1 0,684 0,014 2 , 046 88 , 76 
2 0,742 0 , 012 1, 617 92,28 
3 0,746 0,012 1,609 92 , 54 
r AVERAGE % PURITY = 91,1 9 
It had been intended to assay the Synalar dilutions immediately after 
manufacture, 6 months later and again after one year. However, difficulty 
was experienced in the devel opment of this assay due to the inability to 
isolate the f luocinolone acetonide peak. As a result, the assay was 
fina lly accompli shed 14 months after the preparations had been manufactured. 
All the preparations were found to be within limits apart from the Synalarj 
E45 di lution (see later). The average perc entage purity from three 
individual assays of each preparation are listed below. 
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PREPARATION AVERAGE PERC ENT PURITY 
Synal arjUltrabase 92 , 30 
Synal ar;Buffered Cream 91,42 
Synalar/Emulsifying Oint.ment 91,11 
Synalar /E45 0 , 00 
In the Synalar/E45 dilution no f luocinol one acetonide was found t o be 
present . It is suggest ed that the f luocinol one acetonide , due to the 
alkalini t y of E45 cream has been converted to some other compound. The 
conditions listed above will however, be suitable for the assessment of 
the amount of f luocinolone acetonide present i n a f reshly prepared 
dilution of Synalar/E45. 
The chromatograms for the above assessments are shown on pages 99 and 100. 
4.5 TH E HPLC ASSESSMENT OF BETAMETHASONE 17-VALERATE AND BETAMETHASONE 
21-VALERATE IN BETNOVATE FORMULATIONS 
Assay 
Reagents : 
(1) Water: Distilled. 
( 2) Methanol: Reagent Grade (Merck). 
( 3 ) Iso-Octan e: Reagent Grade (Merck). 
(4 ) 
(5) 
Toluene: Analytical Grade. Interna l Standard. 
Standard Preparat ion. Accurately weigh out approximately 10 mg 
betamethasone 17-valerate authentic specimen and transfer to a 50 ml 
volumetric f l ask. Add 100 ~l internal standard (tOluene) and make 
up to volume with methanol. 
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Procedure 
The procedure is identical to that previousl y described for the Synalar 
dilutions but in this case 100 ~l of toluene is used as the Internal 
Standard. (Page 91) 
Conditions for Use of HPLC 
Solvent: 63% Methanol/37% Water. 
Column: CH-10 Micro Pax 25 em x 2 mm (Varian). 
Detector : 254 nm. 
SENSITIVITY. Detector 0,01 
C.D.8 . 4,00 
Recorder 5 mv. 
The Betnovate dilutions were assayed both 6 and 14 months after manufacture. 
Three separate assays were performed on each formula tion with a minimum of 5 
injections per formulation. 
The average % purity of each di lution determined 6 and 14 months after 
manufacture a r e l isted below and t he respective chromatograms are shown 
on pages 101 and 102. 
PREPARATION AVERAGE % PURITY AVERAGE % PURITY AFTER 6 MONTHS AFTER 14 MONTHS 
BetnovatejUltrabase 95,17 90,22 
Betnovate/Emulsifying Ointment 90,11 91,33 
Betnovate/AqueouS Cream 97 ,1 4 104,16 
Betnovate/Buffered Cream 92,31 91,60 
Betnovate Ha l f Strength 92 , 55 96,49 
Betnovate/Bet novate bas·e 98 , 46 103,22 
Betnovate/E45 95 , 02 62 , 94 
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As can be seen from the above Table, 14 months after manufacture it was 
found that the amount of betamethasone 17-valerate in the Betnovate/E45 
dilution was well below the accepted limits. In addition the chromatogram 
of thi s dilution showed a shoulder on the betamethasone 17-valerate peak. 
It was suspected that this shoulder was betamethasone 21-valerate,and 
therefore., the retent ion time of this shoulder was compared to the retention 
time of an injection of betamethasone 21-valerate. The two retention times 
were shown to be the same. As the conditions li sted above did not effect 
a good separation of the 17- and 21-valerates and as it was desired to 
quanti tate the amount of each isomer present a new assay was developed. 
Assay of Betnovate/E45 After 14 Months 
It was found that an acetonitrile/water mixture proved to be effective 
in causing the separation of the betamethasone 17-valerate and the beta-
methasone 21-valerate. Initially, difficulties were encountered when 
using this mixture as the mobile phase as it was found that, when the 
steroid was dissolved in either methanol or acetoni trile and injected 
onto the column, there was a large baseline shift due to a refractive 
index change of the mobile phase. Changes in refractive index of the 
li quid in the cell changes the amount of light ref lected at the quartz-
l iquid interfaces of the cell. This change in light reflected is 
indistinguishable from absorbed light and results in a shift of the 
dectector base line. 
This could have been overcome by extracting the steroid with the mobile 
phase, but it was felt that the extraction would be more efficient 
using methanol. The detector wavelength was therefore altered from 254 nm 
to 234 nm at which the change in ref ractive index was not detected . 
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The chromatogram (page 100) was considerably shortened and improved by 
increasing the column temperature to 40oC. 
Assay 
Reagents : 
(1 ) 
(2) 
(3) 
(4 ) 
(5 ) 
Water: Distilled. 
Methanol: Reagent Grade (Merck). 
Acetonitrile : Reagent Grade (Merck). 
Iso-Oct ane : Reagent Grade . (Merck). 
Medroxyprogest erone Acetate: Internal Standard . Accurately weigh 
out approximately 0,45 g of medroxyprogesterone acetate authentic 
specimen and transfer to a 50 ml vo l umetric flask. Add 20 ml 
acetonitrile and dissolve medroxyprogesterone acetate with shaking. 
Make up to volume with methanol . 
(6) Standard Preparation: Accurately weigh approximately 10 mg of both 
betamethasone 17-valerat e and betamethasone 21-valerate Authentic 
Specimen~ and transfer to a 50 ml volumetric flask. Add 1 ml of 
in ternal standard and make up to volume wi th methanol. 
Procedure 
The p.rocedure is identical to that previously described for Synalar (page 91) 
but in this case the internal standard is medroxyprogesterone acetate. 
Conditions for Use of HPLC 
Solvent: 45% Acetonitrile/55% Water. 
Column: CH-10 Micro Pax 25 cm x 2 mm (Varian). 
o Column Temperature: 40 C. 
Flow Rate: 70 ml;hr. 
Detector: 234 nm. 
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SENSITIVITY. Detec t or 0 , 2 
C.D.5. 4, 0 
Recorder 5 mv . 
Two individual assays were perfo.rmed , wi th f ive injections per assay. The 
average results for these assays a r e listed below. 
ASSAY MASS OF AMOUNT OF AMOUNT OF PREPARATION B 17-v B 21-v 
1 10,9310 3 , 50 mg 3,15 mg 
2 10 , 5125 3 ,25 mg 2 , 95 mg 
HPLC a llows for a rapid, precise, reliable and reproducibl e method of 
s t eroi d analysis with the additional advantage that it is specific and 
can therefore be used f or stabili t y indica t ions. Unfortunately i t is 
not wi t hout its drawbacks, for the cost of t he inst rument , co l umns and 
so l vent s are high. 
SYNALAR/EMULSIFYING OINTHEln' . 
1 FLUOCINOLOllE ACEI'ONIDE 
2 INTERNAL STANDARD 
2 
Vv 
SYNALARjauFFERED CRFAH 
1 FLUOCINOLON E ACEIaNID! 
2 CHLOROCRESOL 
3 INTERNAL STANDARD 
3 
/I 
2 
, 
v V Vv 
SYNALAR/AOUrotlS CIFAH . 
, FLOOCmOLCl{E ACEI'OJUDE 
2 CHLOROCRESOL 
3 INTEllNAL STANDARD 
2 
3 
\0 
\0 
SYNALAR,I\n.TP.ABASl 
1 PLUOCINOLON E ACETONIDE 
2 INTERNAL STANDARD 
r 
V V V V 
~ 
BEl'NOVATE/FA5 14 M:lNTHS AFT~ PREPARATION 
, BETAHE'rHASON£ 17-VALE:RATE 
2 BErAMEniASON£ 21-VALERATE 
3 INTERNAL STANDARD 
2 
3 
SYNALAR/E45 14 HONTIfS AFTEi PREPARATION 
INTERNAL STANDARD 
IJ y 
~ 
o 
o 
--'I 
BETNOVATr,/EMlILSIF'YlNG OINTHan' 
FLOY 90 mljhr 
, IlITERNAL STANDARD 
2 BETAHE:niASQN£ 17- VALERATE 
2 
BE.1'NOVATE HAlf' STRFliG'I'H 
f'1()l/ go ml;hr 
, INTERNAL STANDARD 
2 BE:l'AMemASONE 17_VALERATE 
2 
BerNOVATEjULTRABUE 
FLO'i 80 ml,/hr 
1 INTE?NAL STANDARD 
2 BETAHEI1iASONE 17- VALDV.TE 
~ 
o 
~ 
2 
BE.TNOVATF/AOumus CREAM . 
FLOW 80 ml,lbr 
1 INTERNAL STANDARD 
2 BF:l'AKrniASONE 17- VALERATE 
2 
BErNOVATF/'BUfFfl:.ED CREAM . 
FLOW 80 ml,lbr 
1 INTERNAL STANDARD 
2 BF:l'AHEI'tiASONE 17- VALERATE 
2 
BETNOVATF/BEI'NOVATE BASE 
FLOW 90 ml,1br 
1 INT ERNAL STANDARD 
2 BETAKEmtASONE 17- VALEllATE 
~ 
o 
'" 
2 
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APPENDI X A 
% TPS VERSUS TIME FOR ALL THE IN ~ ASSESSMENTS. 
ABBREVIATION 
B 
B/A 
B;B 
B;Bb 
B;H 
Bju 
B/E 
B/45 
S 
S/A 
SiB 
S/E 
sju 
S/45 
SiD 
S/F 
.A 
B/C 
B/b 
E 
U 
45 
Sib 
PREPARATION 
BEI'NOVATE CREAM 
BEI'NOVATE/AQUEDUS CREAM 
B EI'NOVAT E,lBUFF ERED CREAM 
BEI'NOVATE;BEl'NOVATE base 
BEI'NOVATE HALF STRENGTH 
BEl'NOVATEjuLTRABASE 
BEI'NOVATE/EMULSIFYING OINTMENT 
BEl'NOVATE/E45 
SYNALAR 
SYNALAR/AQUEDUS CREAM 
SYNALAR;BUFFERED CREAM 
SYNALAR/EMULSIFYING OINTMENT 
SYNALARjuLTRABASE 
SYNALAR/E45 
SYNADONE CRFAM 
SYNALAR FORTE 
AQUEOUS CREAM 
BUFFERED CREAM 
BEl'NOVATE BASE 
EMULSIFYING OINTMENT 
ULTRABASE 
E45 
SYNALAR BASE 
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TIME 7 8 10 12 14 16 18 24 28 
FIG . 1 
2 STRIPES 17,4 25 , 0 35 , 9 40 , 0 37 , 6 28 , 3 19,2 3,7 2 , 2 
3 STRIPES 21,9 29 , 4 46 ,1 49,4 42 , 6 32 , 4 23 ,2 8 ,0 5 , 2 
4 STRIPES 25 , 9 33 ,0 49 , 3 55 , 0 49,1 37 ,4 28,2 6,7 4 , 3 
5 STRIPES 30 ,0 35 ,7 55 ,1 58 , 0 49 , 3 38 , 2 28 , 5 6 , 3 4 ,1 
FIG. 2 
5 STRIPES 34,8 40 , 2 51,7 55 , 9 54 , 0 52 , 0 42 ,8 8,1 7 ,6 
6 STRI PES 39,2 45 , 3 55,9 60,6 56 , 6 55 , 6 46 , 5 9,1 7,9 
7 STRIPES 38 ,7 44,9 56 , 6 62 ,1 58,9 55 ,7 47 , 3 8,8 8,4 
8 STRIPES 41,6 44 ,4 56 ,2 61,3 57,9 56 ,9 48,3 10, 8 9,6 
TIME 4 , 5 6 , 5 9 10 12 14 16 18 24 28 
FIG . 3 
2 HOURS 2 ,5 7,3 11 , 2 11 ,4 14 , 2 15,1 12 , 0 10,2 1,9 0 , 01 
~ HOURS 7 , 6 9 ,3 18 ,1 25 , 5 30 , 3 32 , 2 27 , 6 24 , 8 7 ,3 3, 7 
~ HOURS 16 , 2 22 ,1 29 , 6 38,6 40 , 9 37 , 2 31, 7 6 , 8 4 , 6 
~ HOURS 25 , 9 32 ,7 43 , 7 50 , 7 46,2 40 ,1 12,1 7,2 
rrME 9 11 12 , 5 14 16 18 20 22 24 36 
PIG. 4 
8 HOURS 31, 7 35 , 2 53 ,2 58 , 2 61 , 5 51,2 46 ,2 40,8 32 ,7 5 , 8 
o HOURS 38 ,9 52 , 8 62 , 3 69,5 55 , 9 51 ,1 45, 6 36 , 3 5 , 5 
2 HOURS 56, 9 65 ,0 68, 5 61, 2 54 ,1 46,2 36 ,4 6 , 5 
- 11 2 -
TIME 7 ! 8 10 12 14 16 18 24 28 
FIG . 5 
B 5,1 6 , 9 7,9 9,7 10 , 2 12,5 10,2 3, 7 1,9 
B/A 9,9 6,6 8 , 6 11 ,1 11,9 15,2 9, 9 0, 8 0, 8 
B/Bb 6,2 6, 2 6,2 8 , 3 8 , 0 8,6 8 , 3 1, 2 0,9 
B,Al 5 , 1 6 , 9 7,9 9, 7 10 , 2 12, 5 10, 2 3, 7 1,9 
B;U 4,7 6 , 2 7,4 8 , 2 9,3 7, 0 4,7 1, 6 1,2 
FIG . 6 
B 17,3 26 , 7 40,7 49 , 8 50 , 6 43,2 35 , 0 9 ,1 6 ,2 
B/A 9,9 12, 3 34,2 37 ,9 40 , 0 33 ,7 30,0 9,9 7,0 
B/Bb 11 ,1 15, 4 32 ,1 38 ,0 40,7 36 ,1 25 , 9 5 , 5 4,9 
B,Al 10 , 7 19,8 35 ,8 39,1 43, 2 37,4 30 ,9 6 , 6 5 ,3 
Bju 7 , 3 12, 8 31,6 38,0 37 , 6 35 ,0 25,2 6 , 8 5 , 5 
FIG . 7 
B 22,2 31, 2 41,2 50 , 5 54 , 5 43,9 35 , 7 16,4 11 ,6 
B/A 18 ,1 23 ,0 35,7 44,2 44,4 35,1 30 , 0 12,4 10 ,6 
B/Bb 16, 9 24 , 8 36,9 44 , 7 44,9 35 , 7 29 , 3 11 ,6 8 ,7 
B,Al 16 ,4 24,1 33,3 41,4 43,S 31 ,9 25 , 7 10 ,4 8 , 3 
B/U 15, 8 21, 8 32,3 40 , S 41, 8 33 ,9 28,3 12,3 8 , 8 
FIG. 8 
B 25 ,9 32 , 9 42,9 49 , 2 47 , 2 37 , 4 24 , 3 5,9 3,2 
B/45 25,0 28 ,1 36,S 45,0 42,8 33,7 23 ,9 6 , 5 3 , 9 
B/B 24 , 0 29 ,0 40,3 46,4 46 , 2 35,S 34 , 6 8 , 5 4 , 0 
B/E 22 ,4 26 , 7 36 , 8 45,3 42 , 8 35,6 28 ,0 9,9 5 , 6 
Bb 7,3 6,8 2,0 4 , 3 1,5 2, 3 1,8 1, 0 0 , 5 
.. 
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\ i I I I 28 I TI ME 7 8 10 12 14 I 16 18 24 I I I 
FIG . 9 
B 22,2 34,6 43,4 44,0 43 , 6 39 , 5 31,9 12,1 8.4 
B/A 29 , 2 35 , 8 43 ,4 47, 5 47 , 2 37 ,9 30 , 5 10, 3 6,3 
B;Bb 24 ,4 32 , 7 40,7 41,9 42 ,1 33,2 25, 8 8 ,4 5,7 
B;H 23 ,2 31,5 41,9 41,9 41,1 31,6 23,9 8,7 4,3 
Bju 27 , 2 35 , 8 43 ,4 45,3 44 , 2 36 ,0 28 , 9 9,5 4, 5 
FIG. 10 
B 25 , 6 31, 6 42,5 48 , 8 47 , 5 35 ,1 28 , 6 11,7 8,0 
B/45 30 , 0 35 ,3 43 ,0 45 , 2 43,6 29 ,3 19, 7 9, 8 3 , 6 
B/B 23 ,7 29,5 37,6 39,7 39 ,4 30 ,3 24,2 8,8 4, 5 
B/E 22 , 5 29 ,2 38 ,1 44 ,2 38 , 3 30 ,0 24 ,4 9,4 4 , 2 
U 4,2 5 , 6 5 , 3 4 , 7 5 , 3 4,7 3,6 2,5 2,2 
FIG. 2.1. 
B 29,0 37,7 51, 5 63,9 64 , 5 54 ,0 50 ,2 17, 3 15,4 
B/A 29 ,9 36 , 8 53,5 65 , 6 61,8 52 , 8 50 ,0 19 ,4 13, 5 
B/Bb 22 , 6 33 , 7 44 ,1 59 , 7 58,3 49 ,7 45 , 5 13,2 12, 2 
B;H 27 ,4 37,2 50 ,3 60,8 60 ,4 50 ,7 48,0 12,8 10, 4 
Bju 31, 6 39,6 55,9 64,9 63 , 2 53 , 5 51,4 14,9 14, 2 
FIG. 12 
B 28,3 31, 3 39,4 50 , 7 47 ,4 43 , 5 29,6 8 ,8 4,8 
B/45 22,6 25,0 30,2 43 , 9 43 , 2 44 , 6 33 , 3 11 , 3 8,0 
B/B 24,3 29,6 37,5 53,5 49 ,4 45,9 35 ,9 10,6 6,3 
B/E 16 ,7 20 , 4 25 ,0 39 , 8 38 , 7 42 ,4 29 , 3 9,6 8,0 
E 8,0 7,6 7 ,1 5 , 0 2 , 1 1,5 1,0 1 , 1 0, 7 
, , 
• 
, 
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TIME 7 8 10 12 14 16 18 24 28 
FIG. 13 
B 19 , 3 25 , 8 42 ,4 52, 2 49 , 8 44 , 9 29 , 1 5, 1 4 , 0 
B/A 29 , 5 30,4 51, 0 54 ,6 53 ,1 46 , 9 32 , 0 6 ,1 3, 4 
B/Bb 27 , 6 34 , 1 52,4 59,9 57 , 5 53 , 2 34 ,1 6 , 7 3, 6 
B;H 26 , 3 30 , 6 48 , 5 55, 8 55 , 3 48 , 5 33 , 8 6 ,1 3 , 2 
B;U 25 , 7 29 , 7 48 , 3 53 , 7 55 , 6 46 , 7 31, 7 5 , 3 3, 4 
FIG. 14 
B 19, 3 31, 3 45 , 8 54 , 2 50 , 3 34 , 4 27 , 3 5 ,0 1, 8 
B/45 22 , 6 34 ,6 47 , 7 55 , 6 52 , 6 36,7 27 , 2 4 ,1 3 ,1 
B/B 19 ,0 30 , 2 44,5 49 ,7 49 , 5 37 , 0 26 , 0 4 ,4 2, 9 
B/E 16,7 25,5 41, 2 47 ,9 46 , 6 33 , 9 25, 8 2, 1 2 ,0 
FIG . 15 
B 24 , 3 31, 5 44, 4 49 ,6 51,4 42 , 6 30,7 8 , 2 6, 0 
B/45 24, 5 26 , 7 28 , 5 40 ,9 44 ,0 47, 3 21, 8 5 , 6 4 , 7 
FIG . 16 
, 
S 12, 2 16,9 28 , 9 35, 0 37 , 7 33 , 3 30 , 0 12, 7 11 , 6 
S/A 12, 8 13, 3 21,1 28 ,9 32, 2 27 , 8 25 , 6 11 , 9 8 , 9 
sjB 10, 6 14, 2 18, 6 26 ,1 32 , 5 28 , 6 29 ,4 12, 5 12,0 
S/E 10 , 8 11,9 20 ,0 25 , 8 31, 4 26 , 1 22,8 7, 7 6 , 4 
B/C 3, 5 3 ,0 2, 8 2, 5 2 , 3 2, 5 2, 5 0,25 . 0 , 25 
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TI ME 7 8 10 12 14 ! 16 I 18 24 28 J 
FIG. 17 
S 20,2 24 , 2 39,3 50 , 0 53 , 6 52 , 8 49 ,4 20,0 16,7 
s/45 12,3 17,3 25,0 39,8 41,0 42,7 39 ,4 15,2 13 ,0 
sjb 8,9 13 , 5 20 ,5 29,0 28,3 27 ,9 25,6 10,7 8,7 
sju 9,5 12 ,9 20 ,0 27 , 3 28 ,9 28 , 9 26, 5 12, 7 9 , 5 
A 11 ,5 6 , 2 4,6 4 , 6 0,8 0,8 0 , 8 2,3 2, 3 
FIG. 18 
S 26,4 32 , 5 47.4 58 .9 55 ,6 50,6 49,4 19, 7 17 , 9 
s/A 29 ,0 33,0 52,5 57,1 61 ,1 50,3 48,2 22,5 18, 5 
siB 33,3 42,2 57,1 66,2 62,6 53,5 50 , 3 21,5 18,9 
s/E 20 ,3 22,2 36 ,9 49 , 7 48 ,1 43,3 41,7 23,1 18 , 3 
45 2 ,7 4 ,2 6,9 3 ,4 2,1 2 ,1 1, 7 0,4 2 ,1 
FIG. 19 
S 11 ,6 17 , 6 29 ,2 40,6 39,4 37 , 9 35 , 5 15, 5 13, 3 
s/F 24 ,6 32 , 5 48,2 64,9 65 , 8 60 , 5 56,4 30,7 28,9 
s/45 13,7 18 , 3 26,9 37 , 7 39,8 35 ,1 30 ,7 13,7 12,9 
sju 9,8 13, 4 23,5 33,3 34 ,9 31,0 27 , 1 10,6 9,6 
sIb 2,9 3,9 2,3 4 , 2 1. 3 1, 0 I 0 , 0 0 , 3 0 , 3 I , . 
FIG. 19 continued 
TIME 30 33 48 
s 12,9 11, 6 5 , 3 
s/F 27,1 25 ,1 12 ,9 
s/45 11,8 8 ,2 3 ,1 
sju 8,6 7 ,8 2,8 
sIb 0, 7 0 , 3 0,7 
• 
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I i i , I TIME 7 8 10 12 14 I 16 18 24 I 28 I 
FIG. 20 
S 20 , 8 28,1 36 , 6 47 , 2 56,1 52,5 50 , 6 20 , 3 17,2 
S/A 25 , 8 35,6 45,0 56 , 4 65 , 3 59,7 56 ,1 19,4 15,3 
s/B 23,1 31, 3 42 , 5 54 , 7 60 , 3 58 , 6 50,8 17 , 5 11, 9 
S/E 11,7 19, 4 33,1 43,1 52,2 52,2 47,8 18, 1 12,2 
FIG. 21 
S 12, 2 16,9 28,9 35 , 0 37,8 33,3 30 ,0 12,8 11,7 
S/45 8,3 15, 3 21,7 26,4 31 , 7 26 , 4 21 ,4 10,8 10,0 
sju 11,4 16, 7 21,4 28 , 6 28,6 26,4 26,7 13,3 11,7 
FIG. 22 
S 16 , 7 22,8 35 , 1 38, 5 38,6 36,7 28,4 8,4 8,0 
S/A 10, 8 16,2 24 , 5 27 , 5 28,4 27,8 20 ,4 8,3 7 , 5 
s/B 10,4 18, 5 27 ,4 28,9 32,0 30 , 5 24,5 8,0 7,0 
S/E 6,3 11, 5 16,7 19,3 20,8 18,9 15 ,2 6,0 4,5 
FIG. 23 
S 16,7 22,8 35,1 38,5 38,6 36,7 28,4 8,4 8, 0 
sju 9 , 3 16,1 22,6 25 , 4 26 , 4 23,7 19 , 7 6, 3 5,6 
S/45 9,3 14,4 16,9 17,4 14 , 9 11 , 1 9,5 3,0 2 , 6 
FIG. 24 
S 11 , 1 12,8 17 , 5 17,7 17,7 16 , 9 14,8 6,4 6,8 
S/45 9,1 7,4 8,4 5,1 6,4 6,8 3,7 2,1 2,1 
i 
